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Alzheimer’s disease (AD) is a complex, multifactorial, and rapidly neurodegenerative disorder 
characterized by cognitive impairment and progressive dementia. Its pathology was first 
characterized by Alois Alzheimer as “a peculiar disease of cerebral cortex” in 1907. Amyloid beta, 
tau and cholinergic hypotheses are at the forefront of AD research. The currently available 
treatments that follow the traditional approach of “one target, one drug” are insufficient to treat 
AD and with the growing number of patients and an aging population developing novel derivatives 
as potential treatment for AD is critical. We believe that aminoadamantane derivatives can be used 
as suitable scaffold for developing treatments that can inhibit the aggregation of Aβ due to their 
favorable lipophilicity, safety profile and ease of chemical modifications. The goal of this project 
was to develop a library of novel aminoadamantane derivatives with suitable pharmacophores that 
exhibit Aβ aggregation inhibition properties. A total of 48 derivatives were synthesized and 
biologically evaluated in vitro for their potential Aβ anti-aggregation activity and structure-activity 
relationship (SAR) data was analyzed. The molecular docking studies of the lead candidates were 
investigated to gain insight into their mode of action. The most potent Aβ40 inhibitor was 2n  (4-
amino-N-(3,5-dimethyladamantan-1-yl)benzamide; (Aβ40 IC50 = 0.4 μM)), closely followed by 2l (N-
(4-bromobenzyl)-3,5-dimethyladamantan-1-amine; (Aβ40 IC50 = 1.8 μM)) and 3m (N-(1-(adamantan-1-
yl)ethyl)-3-aminobenzamide; (Aβ40 IC50 = 1.8 μM)). In conclusion, this project provides a new class 
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1. Chapter 1: Introduction 
1.1 Alzheimer’s Disease 
“I have lost myself” replied Auguste Deter to Dr. Alois Alzheimer when she was asked to write 
her name.1 November 3rd 1906, more than a century ago, marks the discovery of Alzheimer’s 
disease (AD). AD is a multifactorial neurodegenerative disorder with a complex pathophysiology, 
rapidly growing number of patients, and substantial socioeconomic burden on healthcare systems 
across the world.2,3,4  In Canada, estimated 747,000 patients exhibited various degrees of dementia 
with 550,000 , almost 70% of cases, being attributed to AD. With a combined direct medical and 
indirect costs of 24 billion dollars in Canada and 236 billion dollars in the US in 2015, it’s no 
surprise that AD is the most costly disease in North America. According to Alzheimer’s association, 
by 2050 the cost of treating AD patients will rise to a staggering 1 trillion dollars in North America 
due to an aging population and increase life span of individuals.5,6,7  AD pathophysiology mainly 
affects elderly population; however, genome-wide associated studies have identified APP, PSEN1, 
PSEN2 and APOE4 genes as genetic risk factors associated with early-onset of AD (EOAD).8 
The neuropathology of AD is mainly characterized by the abnormal deposits of extracellular 
amyloid beta (Aβ) and intraneuronal hyperphosphorylated tau (τ) proteins. Although substantial 
effort was focused on these two proteins, various hypotheses have been put forward to describe the 
complex pathophysiology of AD. Among those, cholinergic, Aβ, tau and oxidative stress 
hypotheses were on the center of AD research focus (Figure 1.1).9,10 However over the past decade 
a number of new mechanisms have emerged expanding the complexity of AD such as 
neuroinflammation, diabetes, N-methyl-D-aspartate (NMDA) excitotoxicity and receptor for 
advanced glycation end products (RAGEs).11,12     




Figure 1.1: Schematic outline of AD pathophysiology with respect to major hypotheses: Aβ, tau 
and cholinergic dysfunction. 
Currently available pharmacotherapy options for AD is only limited to three cholinesterase 
inhibitors, donepezil, galantamine and rivastigmine and one NMDA antagonist; memantine (Figure 
1.2).13 The aforementioned pharmacotherapies only provide modest symptomatic relief for a short 
period of time with no disease-modifying effect (DME) except for galantamine.14 Alarmingly, it’s 
been more than two decades since any potential treatments have passed the clinical trials and 





Figure 1.2:  Currently approved treatments for AD. 
This shortcoming is due to an age-old approach in pharmaceutical industry of “one-target, one-
drug, one-disease”, which begs the question of will this approach eventually lead to the development 
of a cure for AD? The short answer is NO! With such an intricate disorder and many layers of 
complexity, growing list of genetics and environmental risk factors and lack of early detection, 
developing multitargeting treatments seems to be the only logical approach in tackling AD as 
evident in the recent focus of scientific community on developing such treatments.16  
 
1.2 Amyloid hypothesis 
 Aβ peptide was first identified in 1984 as the major component of Aβ plaques by Glenner and 
Wong who demonstrated that it’s a 4.2-kDa peptide primarily 40 to 42 amino acids in length.17,18 
Its role in pathophysiology of AD eluded the scientists until 1992, when Hardy and Higgins 
postulated that  the aggregation of Aβ peptide into Aβ plaques is the causative agent in AD.19,20 
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Although more than two decades of research have added more layers of complexity to the 
pathophysiology of the disease, the main body of the hypothesis is still accepted within the scientific 
community. It is noteworthy that the formation of Aβ plaques have been linked to many medical 
complications such as Parkinson’s disease (PD), type 2 diabetes and a number of cancers.21,22 AD 
is not an all or nothing phenomena, its pathophysiology takes years, in some cases decades to 
develop. Interestingly, up to 40% of elderly individuals show significant load of Aβ without any 
signs of cognitive impairment. This observation is in direct conflict with Aβ hypothesis and to 
address this conundrum it is essential to examine various stages of AD as summarized in Figure 
1.3. 
 
Figure 1.3:  Various clinical stages of AD and its progression. Mild cognitive impairment (MCI).  
As Figure 1.3 indicates, the Aβ pathology starts while the patients experience a long 
asymptomatic phase with normal cognitive functions while AD pathology is well underway and a 
 5 
 
symptomatic phase where patients exhibit rapid decline in global cognitive functions, changes in 
personality, mode, behavior, motor apraxia and eventual death.23,24,25 The pathology of Aβ by itself 
is incapable to lead to the development of AD by patients, it’s rather than the conjunction of Aβ and 
tauopathy that leads to the diagnosis of AD.  
 
1.3 Amyloid Precursor Protein (APP) 
Aβ originates from Amyloid Precursor Protein, a family of type 1 transmembrane proteins that 
is mainly expressed in synapses of neurons. The primary function of APP is not fully understood 
however, various studies have linked APP with cell health and growth, signaling, metal 
homeostasis, neuronal plasticity and synapse formation.26,27 The APP gene is located on the long 
arm of chromosome 21 containing 18 exons and spanning approximately 240 kb. Through 
alternative splicing eight isoforms are generated ranging from 365 to 770 amino acids in length, 
three of which, 695, 751 and 770 isoforms are more ubiquitously expressed. The biological 
incorporation of APP in the synapse and neuronal cellular membrane consists of a large N-terminal 
extracellular domain, ~600 amino acids, and a short hydrophobic C-terminal intracellular domain 
(Figure 1.4).28,29 A number of point mutations and duplications of APP have been identified to 
impact the metabolic pathway of APP and lead to familial Alzheimer’s disease (FAD), 5-10% of 
AD cases, which co-segregate with autosomal dominant inheritance of APP, presenilin 1 (PSEN 1) 
and presenilin 2 (PSEN2). These mutations lead to over production of Aβ peptides promoting the 
development of AD.8,30,31  
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Figure 1.4: Schematic representation of APP and three secretases. 
 
1.4 APP metabolism and processing  
APP metabolic routes lead to two pathways, non-amyloidogenic pathway which refers to the 
formation of Aβ peptides incapable of aggregating and amyloidogenic pathway.29,32,33 APP is 
processed via alpha (α), beta (β) and gamma (γ) secretases where the sequential cleavage by α- and 
γ-secretases lead to non-amyloidogenic route, however the sequential cleavage by β- and γ-
secretases give rise to amyloidogenic route (Figures 1.5 and 1.7). 
The non-amyloidogenic pathway is mediated by α-secretase within the extracellular domain 
very close to the cell membrane, cleaving APP between lysine-16 and leucine-17 (based on the Aβ 
peptide numbering) results in the shedding of a large soluble APP fragment, α-APPs and a 
membrane-tethered intracellular C-terminal fragment, CTF-83.34,35 It is noteworthy, that there is no 
single α-secretase, rather a large family of proteolytic proteins referred to as ADAM (a disintegrin 
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and metalloprotease), with ADAM 9, ADAM 10 and ADAM 17 are of greater importance in AD 
pathology.36,37 
 
Figure 1.5: Schematic of APP processing via non-amyloidogenic pathway. 
The CTF-83 is further processed by γ-secretase producing an amyloid intracellular domain 
(AICD) fragment and a 3-kDa peptide referred to as p3 or Aβ 17-40/42, although the exact 
biological impacts of these fragments remains enigmatic, recent studies suggest Aβ 17-40/42 can 
also deposit in brains of AD and Down Syndrome patients.38 
The biological functions of α-APPs is extensively researched and well understood and 
broadly speaking, α-APPs exhibits neurotrophic and neuroprotective effects.39,40 α-APPs is present 
early in brain development and stimulates the neural-progenitor proliferation and has potent 
neuroprotective effect against glutamate neurotoxicity. It can also modulate the APP processing by 
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directly interacting with β-secretase and disrupts the interaction between β-secretase and APP, 
lowering the production of Aβ peptides. The neuroprotective effects of APP has been observed in 
vitro studies and attributed to the C-terminal segment of the fragment, residues 591-612, which is 
absent in β-APPs.41,42   
 
 
Figure 1.6: Schematic representation of various domains of APPs. 
In the amyloidogenic pathway APP is first processed by β-secretase, also known as β-site 
APP cleaving enzyme 1 (BACE1), generating a membrane-tethered intracellular C-terminal APP 
fragment (CTF-99) and a large soluble N-terminal fragment β-APPs. It is worth mentioning that 
developing inhibitors of β-secretase is considered a desirable therapeutic option for AD.43 The β-
APPs fragment is not subjected to further processing and shares the same amino acid sequence as 
α-APPs apart from the last 16 C-terminal amino acids, known for its neuroprotective properties. 
Although β-APPs exhibits some degrees of neuroprotective effects, it’s up to 100-fold less potent 




The CTF-99 contains Aβ fragment and similarly like CTF-83 is processed by γ-secretase 
and cleaves between Valine 711 and Isoleucine 712 or Alanine 713 and Tryptophan 714 releasing 
a full length 4.2 kDa Aβ40 and 42 respectively alongside with AICD fragment.46,47 It is noteworthy 
that both amyloidogenic and non-amyloidogenic pathways are part of normal physiology in brain 
although the non-amyloidogenic pathway is more dominant and there are mechanisms in place in 
healthy brain to handle the various fragments mentioned before.48 In AD patients the delicate 
balance between these two pathways is disrupted resulting in a shift towards amyloidogenic 
pathway, leading to the higher rate of production of Aβ40 and 42.     
     
 




1.5 Aβ Structure, Function, Aggregation and Clearance 
Although Aβ40 and 42 are the most common forms of this peptide, Aβ peptides vary in 
length from 36 to 43 amino acids as APP processed by γ-secretase. Aβ40 and Aβ42 peptides are 
among the most common variations of the peptide with Aβ40 being the most common product of 
APP cleavage by γ-secretase  and Aβ42 being the more toxic form and more susceptible to aggregate 
into plaques due to its greater hydrophobicity (Figure 1.8).49,50 
     
Figure 1.8: Aβ peptide sequence. 
Native Aβ peptides at monomeric state are nontoxic and presumably unfolded with 
unordered structures (Figure 1.9).51 The main driving forces in the aggregation of Aβ peptides into 
higher ordered assemblies such as dimers, trimers, oligomers and fibrils are only partially 
understood, however concentration of the peptide, temperature and the pH can drastically impact 
the rate of aggregation process of Aβ as presented in Figure 1.9.52,53 The transition from unordered 
structures into misfolded peptides enriched in β-sheets initiate the aggregation process. This 
transition step is mainly associated with the exposure of hydrophobic segment of Aβ, the KLVFFA 
domain (amino acid residues of 16 to 21), however acetylcholinesterase (AChE) and certain metal 
ions can also facilitate the misfolding and aggregation process.54 The misfolded monomers 
aggregate to each other via hydrophobic interactions and hydrogen bonding in order to form higher 
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order structures ranging from dimers to heptamers, eventually grow into soluble oligomers. 
Protofibrils are assembled from oligomers and through elongation mechanism form mature Aβ 
fibrils. In the elongation phase, Aβ monomers interact with the N-terminal of Aβ protofibrils via 
hydrogen bonding, resulting in the formation of the bent β-hairpin structure which eventually 
associates into Aβ fibrils.55,56 Interestingly, the severity of the disease and synaptic loss correlates 
more closely with the Aβ oligomers load rather than with the Aβ fibrils (Figures 1.9 and 1.10).    
 
Figure 1.9: Illustration of self-induced Aβ Aggregation pathway.  
 




Although the aggregation of Aβ pose a variety of issues in brain, there are a number of 
mechanisms in place to deal with the post production of Aβ. Receptor-mediated transport of Aβ 
across BBB and enzymatic degradation are the first line of defense in body to maintain the Aβ level 
at its physiological concentration.57,58 However, recent studies point to the presence of endogenous 
autoantibodies against Aβ in AD patients and healthy individuals at very low concentration. The 
interstitial fluid (ISF) bulk flow is responsible for the removal of soluble Aβ across BBB into the 
bloodstream while receptor-mediated clearance is the primary route of Aβ transport across BBB, 




Figure 1.11: Schematic representation of Aβ removal/degradation in body. LRP and RAGE are 
implicated influx of Aβ across BBB while the major degradation of Aβ is fostered by NEP, IDE 
and ECE.    
 Low-density lipoprotein (LRP) and RAGE are the primary receptors involved in the flux of 
Aβ and a number of other proteins across BBB.60,61 While LRP mediates Aβ efflux from brain 
interestingly, RAGE has been implicated in influx of Aβ into the CNS. The expression of LRP is 
suppressed in Aβ rich environment while RAGE expression is unregulated in such an environment 
completing a positive-feedback cycle, eventually diminishing the Aβ clearance via mentioned 
receptors. It is noteworthy that Aβ clearance in brain diminishes with age regardless of the health 
status of individuals.  Aβ degradation via enzymes is mediated by a few zinc-bound peptidases, 
neprilysin (NEP), insulin-degrading enzyme (IDE) and endothelin-converting enzyme (ECE) 
(Figure 1.11).62,63,64  
 
1.6 Aβ Pathology and physiology  
The tissue degeneration in AD is associated with the formation of Aβ fibrils 7-10 nm in 
diameter, the Aβ toxicity is mediated via several mechanisms including, oxidative stress, 
mitochondrial dysfunction, inflammation, synaptic dysfunction, excitotoxicity and alteration in 
membrane permeability are among such mechanisms.21,65  
 The neurodegenerative effects of oxidative stress as a major contributor to neuronal loss is 
not limited to AD and is observed in a number of other diseases such as Parkinson’s disease (PD), 
Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS).66,67 Oxidative stress is caused 
by the imbalance in the production and elimination of reactive oxygen species (ROS), a group of 
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oxygen-containing free radicals such as hydrogen peroxide (H2O2) and superoxide (O2
-). ROS is 
mainly generated by mitochondria, organelle responsible for providing the energy for cells in the 
form of adenosine triphosphate (ATP) during oxidative phosphorylation.68 ROS also links amyloid 
hypothesis to mitochondrial dysfunction, where the overproduction of Aβ decreases the activity of 
electron transport chain enzymes by causing deficiency in both complex 1 (NADH dehydrogenase) 
and complex 4 (cytochrome c oxidase) leading to ROS overproduction and ATP depletion (Figure 
1.12).67,69,70 
 
Figure 1.12: Mitochondrial dysfunction in AD. Aβ aggregation causes to oxidative stress, ATP 
depletion and MPTP aperture leading to mitochondrial dysfunction. 
 ATP depletion disrupts neurotransmission, alters axonal transport and metal ion homeostasis 
especially calcium (Ca2+) and sodium (Na+) in neurons which is essential to maintain the membrane 
potential. The other negative impact of ROS upon mitochondria is by stimulating an opening of the 
mitochondrial permeability transition pore (MPTP), a protein channel that passes through both inner 
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and outer mitochondrial membranes resulting in influx of Ca2+ and oxidative stress.70,71,72 
Mitochondrial dysfunction also trigger apoptosis of neuronal cells, the process of programmed cell 
death, although the mechanism behind this is still open to debate.  
Copper and iron metal ions have the ability to form complexes with Aβ plaques and acts as 
catalyst to generate ROS. The ability of Aβ to reduce Cu2+ and Fe3+ to Cu1+ and Fe2+ respectively 
via Fenton cycle is mediated by sulfur atom of methionine amino acid (M35) which can easily 
donate electrons.73,74 This ability is further facilitated considering Aβ contains a metal binding 
domain at the N-terminal segment. The tri-histidines (H6, H13, and H14) and aspartic acid (D1) 
domain chelate to copper, iron and zinc, stabilizing the Aβ oligomers, elongate the lag phase and 
prolong the ROS generation cycle specifically H2O2.  
 The physiological inflammatory response is a self-protection secondary response of body to 
an initial harmful event, like infections. However inflammation has been linked to a number of 
diseases either as the initiation mechanism or progression mechanism such as cancer, heart disease 
and not surprisingly neurodegenerative disorders.75,76 With respect to AD, neuroinflammation is 
viewed as a double-edged blade, where it is beneficial in degrading Aβ, however overstimulation 
can eventually lead to neuronal death. It is mainly associated as a secondary response to Aβ 
deposition, however there are few studies suggesting that neuroinflammation is an ever-present 
driving force in AD pathology. In AD patients, soluble Aβ oligomers and fibrils are able to attach 
to microglia, a highly motile phagocytic macrophage in the CNS, triggering an immune response in 
body by producing pro-inflammatory cytokines and chemokines.77,78 The impaired Aβ clearance 
due to higher concentration of Aβ in AD patients causes the “stimulus” to remains persistent and 





Figure 1.13: Schematic representation of neuroinflammation response to Aβ aggregates. Initial 
response helps with the clearance of Aβ however the sustained exposure and overstimulation leads 
to chronic neuroinflammation. 
  Synaptic plasticity, the ability to strengthen and weaken in response to neurotransmitters, is 
vital in global cognitive function. The loss of synaptic plasticity and long-term potentiation (LTP), 
enhanced level of neuronal transmission, are frequently observed in late stage of AD.79,80 It’s been 
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postulated that synaptic dysfunction in AD patients is due to Aβ oligomer’s ability to bind to 
neuronal receptors on the synaptic cleft and hindering their function. Glutamate (GluR), NMDA, 
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and α7-nicotinic receptors are 
among such receptors.81 
 Aβ is also known to interact with the cellular membrane to form channels in the neuronal 
membrane leading to abnormal flow of metal ions inside and outside the cells.82 It’s been postulated 
that the mechanism behind the formation of these channels are similar to that observed in 
antibacterial agents killing bacteria.    
Finally, there is growing evidence that telomere shortening, a hexanucleotide (TTAGGG) 
repeats located at the 3` end of DNA strands, can play an important part in pathology of AD.83,84 
Telomeres play a vital role in maintaining the stability of genes and during DNA replication, after 
every cell division this segment become shorter and serves as a marker to the history of cell 
replication. In general, the shorter the telomere segment the higher the risk for AD where Aβ 
aggregates inhibit the activity of telomerase, a ribonucleoprotein enzyme that adds the TTAGGG 
segment to the DNA. Recent in vivo and in vitro  studies suggest that Aβ oligomers interact with 




Figure 1.14: The summary of Aβ toxicity mechanims: (a) mitochondrial dysfunction, (b) oxidative 
stress, (c) cell membrane disruption, (d) synaptic dysfunction/toxicity (e) telomerase dysfunction. 
After discussing the Aβ toxicity in great details, it is just fair to explore the positive 
physiological functions of Aβ in maintaining a healthy central nervous system (CNS) mainly 
neurogenesis, synaptic plasticity, antioxidant activity, memory formation, calcium homeostasis and 
metal chelation.88,89 Although at the first glance, Aβ pathological and physiological properties 
appears to be at odds with each other, its crucial to keep in mind that the production of Aβ at the 
basal level serves a physiological purpose, however under certain circumstances this balance tips 
towards Aβ pathology (Figure 1.15). The fate of this balance is mainly decided by the concentration 
of Aβ peptide, where at picomolar (pM) concentration, Aβ exhibits physiological roles however at 
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nanomolar (nM) to micromolar (µM) coupled with aging effects, it shifts towards pathological 
roles.90   
 
Figure 1.15: The balance between pathological and physiological roles of Aβ. Physiological effects 
of Aβ is observed at low concentration (pM) however in AD, elevated concentration of Aβ (nM to 
µM) the balance shifts to pathological effects.  
Recent studies have strongly linked Aβ oligomers to neurogenesis, the process of generation 
and differentiation of neurons and glial cells from neuronal stem cells (NSCs). Aβ40 promotes NSC 
proliferation and neurogenesis whereas Aβ42 is more selective towards gliogenesis of NSCs.88,91 
Growing interest in the use of NSCs in cell therapy opens the possibility to combat the effects of 
neurodegenerative disorders by replacing the damaged or dead neurons. Recent efforts to identify 
the Aβ induced neurogenesis indicates that Aβ isoforms increase the proliferation of NSCs via the 
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activation of PI3K-Akt pathway, an intracellular signaling pathway critical in regulating diverse 
cellular functions such as growth, proliferation and survival.92  
 
Figure 1.16: Schematic representation of physiological effects of Aβ, synaptic plasticity, 
neurogenesis, memory function, metal chelation and antioxidant activity. 
As discussed before, transition metals especially copper and iron play a vital role in the 
production of ROS. Among the many mechanisms in the body to keep the concentration of these 
ion metals in balance, mounting evidence suggest that Aβ acts as metal scavenging agent at lower 
concentrations.93,94 The tri-histidines (H6, H13, and H14) and aspartic acid (D1) domain chelates to 
metal ions and prevents them from participating in redox cycle, acting as a metal chelator and 
antioxidant in healthy neurons and a number of other cells such as neuroblastoma and hepatoma 
cells. In this context, it appears that the Aβ release in response to head injury or disease is a 
neuroprotection response against oxidative stress after which the Aβ is removed from the brain. 
However, the insufficient Aβ clearance in AD patients coupled with the progressive accumulation 
of Aβ complexes with the mentioned metal ions overwhelms the antioxidant defense systems in 




1.7 Aβ Therapy 
At this point it’s obvious that there are many layers of complexity to Aβ hypothesis and Aβ 
plays a prominent role in pathophysiology of AD, however this complexity affords us many insights 
into a diverse potential intervention targets. Preventing the formation of Aβ, blocking Aβ 
aggregation process or even accelerating the clearance rate of Aβ are among these potential 
targets.16,98,99,100 Several therapeutic options are currently being developed mainly focused on the 
reduction of Aβ load in the brain. These options can be broadly categorized in the following 
approaches: 
1. Prevention or reduction of Aβ production 
2. Modulate the Aβ aggregation process 
3. Enhancing Aβ degradation or clearance from brain 
4. Tackle the Aβ neurotoxicity  
Recalling from APP processing, BACE 1 has emerged as a viable pharmacological target to 
reduce the production of Aβ by development of BACE 1 inhibitors (Figure 1.17). The BACE 1 
inhibition has been identified as a potential therapeutic option in the recent years and led to the 
development of a number of promising candidates.101,102 The early designed BACE 1 inhibitors 
proved to be inefficient due to their inability to cross blood-brain barrier (BBB). However, recently 
developed treatments managed to overcome this challenge. The majority of these treatments 
however dropped out of the clinical trials due to toxicity although a few were well tolerated in 
patients. Considering that BACE has two isoforms, BACE 1 and BACE 2, the possibility exists that 
selective BACE 1 inhibitors can cause side effects due to weak or lack of BACE 2 inhibition. The 
hope is to design BACE 1 inhibitors that balance safety and efficacy. In this regard, some in vivo 
studies suggest at least 50% efficacy is necessary to circumvent  Aβ level sufficiently.41,103 It is 
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noteworthy that BACE 1 also cleaves a number other substrate proteins, which means inhibition of 
the enzyme can lead to unforeseen side effects. That said, BACE 1 inhibitors still hold a substantial 
promise in developing a treatment for AD.102 
The other approach in lowering the Aβ production is the up-regulation of non-amyloidogenic 
pathway, as α-secretase competes with BACE 1 in APP processing pathway. The benefit to this 
approach apart from the obvious reduction in Aβ production, is taking advantage of neuroprotective 
properties of α-APPs released in the non-amyloidogenic pathway.104,105 The up-regulation of non-
amyloidogenic pathway can be achieved by promoting α-secretase activity, enhancing the α-
secretase transduction or by modulation of hormones, statins and other neurotransmitters.        
          
Figure 1.17: BACE 1 inhibitors and their impact on downstream pathology of AD. 
Although halting or reducing the production of Aβ is an attractive approach to say the least, by 
the time the majority of AD patients diagnosed with the disease, there is a considerable Aβ load 
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already present in their brains. So what is the best therapeutic approach for these patients? Arguably, 
modulation of Aβ aggregation is the best option for the treatment of these patients as it can provide 
beneficial DME. The surge in the discovery of small molecules as Aβ aggregation modulators in 
recent years is a testament to the popularity of this approach. This strategy can be categorized into 
two groups, anti-aggregation and pro-aggregation of Aβ peptide, with the pro-aggregation approach 
still at its infancy compared to the well-studied anti-aggregation approach.13,106,107 It is important to 
keep in mind that neither of these approaches are perfect stand-alone strategy and they should be 
used in co-therapy with other treatments to maximize the efficacy of the treatment. In anti-
aggregation approach the main purpose is to minimize the conversion of Aβ monomers into Aβ 
oligomers by stabilizing the early formed intermediates, reducing the exposure time of neurons to 
Aβ oligomers and also reduce the rate of Aβ plaques formation.     
Great number of natural and synthetic compounds have been known to modulate Aβ 
aggregation.108 The anti-aggregation approach is based on stabilizing Aβ monomers and early 
formed intermediates to halt or slow down the aggregation process. Curcumin, congo red and orange 
G are known to have anti-aggregation properties towards Aβ (Figure 1.18). Congo red inhibits the 
formation of Aβ fibrils by binding and stabilizing the monomers and early formed intermediates 
and as a result reduces the concentration of toxic, soluble oligomers.109 Curcumin, a naturally 
occurring compound, inhibits the aggregation of Aβ by destabilizing the protein-protein interactions 





Figure 1.18: Compounds with anti-aggregation properties. 
Orange G inhibits the aggregation of Aβ protein by stabilizing the KLVFFA (Aβ16-21) segment. 
Hydrophobic interactions between aromatic rings of orange G and KLVFFA, ionic interactions 
between negatively charged sulfonic groups of orange G and positively charged lysine amino acids 
leads to further stabilization of β-sheet structure of Aβ.112 Along natural and synthetic small 
molecules capable of modulating Aβ aggregation process, peptide-based inhibitors has started to 
thrive in recent years. A 5 to 15 amino acids in length designed to interact with the KLVFFA 
segment have shown to inhibit the aggregation process with high degree of selectivity however the 
poor bioavailability of these peptides pose a major challenge in their use as therapeutic agents.  
The pro-aggregation approach as the name suggests is based on facilitating the conversion of 
Aβ oligomers to its less toxic form; mature Aβ fibrils (Figure 1.19). The main goal in this approach 
is to minimize the exposure of neurons to Aβ oligomers and using Aβ plaques anti-bodies to reduce 




Figure 1.19: Schematic representation of Aβ toxicity and its correlation with Aβ aggregation 
process.   
 
Facilitating Aβ clearance is another approach in Aβ therapy, however it’s more complicated 
compared to the previous approaches. That said, a number of immune-mediated mechanisms have 
been tested to induce active or passive immune response to reduce Aβ load in the test subjects with 
relative success.115,116 In immunotherapy for AD, Aβ-antibodies are raised with high selectivity 
toward various forms of Aβ. Passive immunization via immunoglobulins against Aβ has been more 
successful with Bapineuzumab and Solanezumab reaching phase III with good tolerability. 
However, in neither cases no significant cognitive improvement was observed despite lowering Aβ 
load.117 
As discussed in previous section, certain metal ions have the ability to form complexes with 
Aβ oligomers and fibrils facilitating the aggregation process and enhance their toxicity. Design and 
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development of small molecules capable of scavenging these metal ions and therefore disrupting 
the formation of Aβ-metal complexes in order to minimize the neurotoxicity and restore the metal 
ion homeostasis have gained tremendous popularity. Small molecules with metal scavenging 
properties have been used for decades to deplete overloaded tissues and facilitate their excretion in 
diseases such as Wilson’s disease or hemochromatosis.118,119 In the context of AD, disruption of 
metal homeostasis is a consequence of the disease rather than the cause and simply removing them 
from brain can lead to undesirable side effects.120 As such, development of multitarget compounds 
with Aβ inhibitory and metal scavenging properties may have potential DME, with clioquinol 
derivatives, a small hydrophobic family of molecules, exhibiting moderate affinity for metal ions 





Figure 1.20: Schematic representation of various therapeutic targets in Aβ therapy. BACE 1 
inhibitors (BSIs). 
 
1.8 Other Factors in AD pathology 
  Although the Aβ hypothesis is the main focus of this project, it is essential to address other 
major hypotheses to paint a better picture of AD pathology. Cholinergic hypothesis, the oldest and 
most studied hypothesis with respect to AD, has been the star player in dementia and 
neurodegenerative disorders for many decades.121,74 The hypothesis suggests that the loss of 
cholinergic function and the subsequent decline in the concentration of acetylcholine (ACh) 
contributes to the deterioration of cognitive functions observed in AD. Cholinergic function is 
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mainly rests upon ACh, a neurotransmitter in brain, acetylcholinesterase (AChE) and 
butyrylcholinesterase (BuChE), enzymes in charge of degrading ACh. The importance of 
cholinergic function  in learning and memory function has provided a rationale for therapeutic 
interventions that increase the concentration of ACh or inhibit the activity of AChE and BuChE.122 
Although the main body of the hypothesis is still valid, the poor efficacy of available treatments for 
moderate to severe cases of AD points to the fact that merely targeting cholinergic hypothesis is not 
sufficient and any potential treatment should be a part of multitargeting platform to efficiently 
combat the pathology of AD.123  
The tauopathy is of great interest in AD research as growing evidence strongly links it with 
neurodegenerative disorders.124 The tau hypothesis is centered around the aggregation of 
hyperphosphorylated tau protein into neurofibrillary tangles (NFTs) and the subsequent neuronal 
damage/death. Tau protein binds to and promotes the assembly of microtubules which is vital to 
maintain the cytoskeletal structure and integrity of neurons.125,126 The activity of tau protein is 
regulated through phosphorylation sites present on the protein via various phosphatases and kinases 
such as glycogen synthase kinase 3 (GSK-3), cyclin-dependent kinase 5 (CDK-5) and mitogen-
activated protein kinase (MAPK).127 In healthy individuals, there is a delicate balance between 
phosphorylated and non-phosphorylated species of the protein. However, in Alzheimer’s patients, 
this balance is disrupted. This disruption leads to formation of abnormally hyperphosphorylated tau 
species which results in the protein losing its structural integrity, hence its function. The 
hyperphosphorylated tau then becomes insoluble due to the conformational changes and dissociates 
from the microtubules, leading to impairment of axonal transport and formation of paired helical 





Figure 1.21: Schematic representation of tau cascade hypothesis and the aggregation process of tau 
protein. 
The therapeutic intervention strategies for tauopathy closely mirror those from amyloid 
hypothesis. The inhibition of GSK-3 and CDK-5 to reduce the phosphorylation of tau, modulation 
of tau aggregation and immunotherapy options to remove tau aggregates from CNS.130,131 Among 
these approaches, tau aggregation modulators are less desirable due to high degree of neurotoxicity 
at this stage of the disease. Microtubule-stabilizing strategy is a new approach in tau therapy where 
microtubule-stabilizing agents counteract the functional loss of hyperphosphorylated or aggregated 
tau.132,133       
The impact of NMDA excitotoxicity in pathophysiology of AD is well established. NMDA 
receptor is carried by neurons and is essential in the optimal physiological function of brain and 
overall cognitive functions.134,135 NMDA receptors are highly concentrated in hippocampus where 
activation of the receptor induces LTP and neuronal plasticity as the result. Elevated level of 
glutamate, an amino acid and neurotransmitter in CNS, results in chronic activation of NMDA 
receptor causing excessive amount of Ca2+ influx into neuron and ultimately neurodegeneration 
known as excitotoxicity. Under physiological condition, glutamate is responsible for 70% of 
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excitatory synapses in the CNS where largely postsynaptic AMPA receptors exhibit very fast 
activation/de-activation kinetics. In contrast, NMDA receptors are normally synaptic activated and 
permeable to Ca2+ with slow ligand gated kinetics.136,137 Normally, NMDA receptor is blocked by 
Mg2+ allowing small influx of Ca2+ into neurons for a brief period of time when activated. However 
in AD, due to impaired glutamate uptake/recycling mechanisms, this barrier is removed causing 
excessive amount of Ca2+ influx leading to synaptic dysfunction and ultimate neuronal death. 
 
Figure 1.22: NR1 and NR2 are the two major subunits of NMDA receptor. The activation of 
receptor is triggered when glycine/D-serine and glutamate/NMDA bind to NR1 and NR2 
respectively. Memantine, an NMDA receptor antagonist, can block the receptor and inhibit the 
influx of Ca2+ into the neurons.   
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1.9 Adamantane Derivatives 
Organic polycyclic cage compounds such as adamantane derivatives (Figure 1.23) have 
attracted the interested of medicinal chemists in the past 50 years with their applications ranging 
from anti-viral agents such as human immunodeficiency virus (HIV) and influenza to symptomatic 
treatment of neurodegenerative diseases such as AD and PD.138 Interestingly, unlike many common 
scaffolds such as indole, quinazoline and quinolone, aminoadamantanes are synthetic in nature with 
a very few naturel sources.  
Discovery of anti-viral activity of amantadine sparked an interest in adamantane derivatives 
in 1960s where amantadine, marketed under trade name of Symmetrel, exhibited strong activity 
against Influenza A.139,140 Amantadine has been used as a treatment for Parkinson’s disease in the 
past three decades.141 Amantadine increases the extracellular dopamine levels which results in anti-
Parkinson activity although not all patients exhibit positive response to the treatment and a number 
of patients develop tolerance to its effects. 
Further modification of adamantane and subsequent synthesis of closely related 
rimantadine, marketed under trade name of Flumadine, which displayed even stronger antiviral 
activity and fewer side effects in comparison to amantadine.142 Food and drug administration (FDA) 
approved both these treatments as anti-Influenza agents, however neither one of them are the 
common choice in treatment of Influenza. Since then, a wide range of drugs have been introduced 





Figure 1.23: Examples of drugs and drug candidates incorporating adamantane moiety.  
 
Memantine was designed and synthesized by Eli Lilly and Company, currently marketed 
under name of Namenda, is approved by FDA as a treatment for Alzheimer’s patients with moderate 
to severe dementia.136,143 It is a NMDA-receptor antagonist that blocks the influx of excessive 
calcium induced by overstimulation of the NMDA receptor. Although it has been approved as a 
treatment for AD, overstimulation of NMDA receptor is a common pathway to neuronal damage in 
a number of other diseases such as PD, HIV-associated dementia, Huntington’s disease (HD), 
multiple sclerosis and amyotrophic lateral sclerosis (ALS) making memantine a potential treatment 
candidate for the mentioned diseases.     
Adamantane derivatives as an example of polycyclic cage compounds, present a viable 
scaffold to design and develop treatments for a wide range of disorders not only as a stand-alone 
treatments but also as an add-on to improve the stability and lipophilicity of existing treatments.   
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2 Chapter 2: Hypothesis and Design Rationale 
2.1 Hypothesis   
 
Figure 2.1: Aminoadamantane derivatives as anti-amyloid aggregation agents. 
The polycyclic cage structure adamantane (tricyclo[3.3.1.1]decane) has a chemical formula 
C10H16 (Figure 2.1). The carbon atoms of the three cyclohexane rings in the saturated hydrocarbon 
adamantane are arranged in a diamond lattice structure. This tetrahedral geometry (sp3) of the 
carbon framework provides a very stable conformation. Adamantane derivatives are known to 
exhibit a number of biological activities listed in Chapter 1 (section 1.9). The ring itself can be 
considered as a pharmacophore that can be incorporated in the design of potential therapeutic agents 
aimed toward viral disease, AD and diabetes.  
The lipophilic nature of the adamantane ring provides excellent blood-brain barrier (BBB) 
permeability as exemplified by the aminoadamantane anti-Alzheimer’s agent memantine (Figure 
1.23, Chapter 1). This evidence suggests that the aminoadamantane ring can be explored to design 
and develop potential agents to treat CNS diseases such as AD. In this regard, Dr. Nekkar Rao’s lab 
at the School of Pharmacy is aiming to develop novel AD therapeutics by targeting the amyloid 
cascade hypothesis of AD.144,145,146 Developing therapeutic interventions that inhibit Aβ 
aggregation and as a result prevent the formation of toxic soluble Aβ oligomers and Aβ fibrils 
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appears to be a favorable approach in targeting the Aβ hypothesis. We believe that targeting the 
early stages of Aβ aggregation, by stabilizing the Aβ dimer, trimer or tetramer should prevent the 
formation of toxic Aβ oligomers and fibrils.  
With this background, the objective of this MSc proposal was to design and develop 
aminoadamantane based compound library as potential Aβ aggregation inhibitors. We conducted 
preliminary computational studies of the aminoadamantane ring in the Aβ-dimer assembly (Figure 
2.2) which suggested the potential of aminoadamantane derivatives to bind and stabilize the 
aggregation prone KLVFFA region of Aβ. This investigation suggested two key factors to consider; 
(i) the polycyclic cage compound aminoadamantane itself could provide weak inhibition of Aβ 
aggregation due to its smaller size and (ii) chemical modification of the primary amine to 
incorporate larger substituents would enhance the anti-Aβ activity. 
 
Figure 2.2: Computational modeling of aminoadamantane (A) and N-(adamantan-1-yl)benzamide 
(B) in the dimer assembly of Aβ (PDB id: 2LMN). The ligands are shown as ball and stick cartoon. 
Some polar and nonpolar interactions are shown. 
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2.2 Design Rationale 
 




Based on computational studies, we hypothesized that the caged adamantane can act as an 
amyloid tether by undergoing nonpolar interactions at the C-terminal of Aβ whereas the 
modification of amine functionality (Figure 2.2) can increase the degree of Aβ aggregation 
inhibition properties. In order to study our hypothesis we aim to synthesize a library of benzamide, 
benzyl or phenylethan-1-one substituted derivatives of amantadine or memantine or rimantadine 
respectively (Figure 2.3). Furthermore, the benzamide, benzyl or phenylethan-1-one rings will be 
substituted at either 3- or 4-position with either a Br or NO2 or N3 substituent. This was based on 
the previous evidence which has shown that the presence of a bromobenzene substituent generally 
provides excellent Aβ-aggregation inhibition due to additional nonpolar contacts whereas polar 
substituents such as a nitro or an azide can promote electrostatic interactions with polar amino acids 
(eg: lysine) in the amyloid aggregates and prevent further aggregation into higher order 
structures.144,146 The proposed compound library has CLogP values ranging from 3.5–6.3 which 
was expected to provide a diverse range of structure-activity data. The aminoadamantane library 
will be screened for potential anti-Aβ aggregation activity by using fluorescence based aggregation 
kinetics assays, transmission electron microscopy (TEM) and by computational studies. 
 N-substitution of aminoadamantanes with acetophenone, benzyl and benzoyl groups modulates 
anti-aggregation properties for Aβ due to variation in their conformation. The anti-aggregation 
property is sensitive to substituents at C-3 and C-4 position of either N-acetophenone, N-benzyl or 
N-benzoyl group. Key functional groups (NO2, NH2, N3 and Br) as substituents were identified as 






The proposal aims to synthesize a library of amantadine, memantine and rimantadine based 
derivatives that possess a cage polycyclic adamantane ring system and evaluate their anti-amyloid 
aggregation properties. It is anticipated that the structure-activity relationship (SAR) studies 
obtained will provide a clear understanding on the ability of aminoadamantane derivatives to 















3 Chapter 3: Methodology 
3.1 Synthetic Chemistry  
The overall synthetic routes as highlighted in the following figures were routine and 
relatively efficient. The majority of synthetic routes were adapted from previously published 
literature with various changes to optimize the synthesis and l yields. 
 




Figure 3.1 illustrates the overall setup involved in the syntheses, purification and 
characterization of adamantane derivatives. The reactions were carried out using appropriate 
solvents based on the nature of reactions, solubility of reagents, and heated or refluxed for certain 
period of time based on the reactivity. Then the solvent was evaporated in vacuo followed by three 
extractions with the appropriate organic solvent (EtOAc, DCM or ether) to isolate the crude product. 
The organic layer was dried using MgSO4 as drying agent and filtered to remove MgSO4. TLC was 
performed to establish the solvent system suitable for the purification of the target derivatives 
followed by column chromatography to afford the final compounds. 
The characterization of purified derivatives were carried out by proton nuclear magnetic 
resonance (1HNMR) spectroscopy to establish and confirm the identity of derivatives. The purity 
(95% or greater) of the synthesized derivatives was confirmed by using LCMS or HPLC. 
3.1.1 Synthesis of benzamide, N-benzyl and phenylethan-1-one substituted derivatives of 
amantadine, memantine and rimantadine (1a-l, 2a-l and 3a-l) 
The benzamide, N-benzyl and phenylethan-1-one substituted derivatives were synthesized 
via alkylation of primary amine starting from either amantadine or memantine or rimantadine by 
using various substrates (unsubstituted benzoyl chloride, 3-or 4-nitrobenzoyl chloride, 
unsubstituted benzyl bromide, 3- or 4-bromobenzyl bromide, 3-or 4-nitrobenzyl chloride,  
acetophenone and 1-(4-nitrophenyl)ethan-1-one) to obtain 1a-l, 2a-l and 3a-l. Figure 3.2 provides 
the chemical structures of the synthesized derivatives. The chemistry procedures to synthesize the 





Figure 3.2: The synthesized benzamide, N-benzyl and phenylethan-1-one substituted derivative 
library.  
Figure 3.3 outlines the underlying mechanism of the alkylation of amantadine with benzoyl 
chloride. Primary amines can react as nucleophiles with benzoyl chlorides via nucleophilic 
substitution (SN2) to produce the target derivatives (benzamides). The reaction is also known as 
benzoylation or Schotten-Baumann reaction. The lone pair of electrons on the nitrogen (N) atom of 
amine attacks the electron deficient carbon (C) of benzoyl chloride as shown in Figure 3.3. In SN2 
reactions, the formation of the bond between N and C and the breaking of C-X bond occur 
simultaneously. These reactions generally use a base to quench the acid formed. Catalysts such as 
copper iodide (CuI) can enhance the reactivity of benzoyl chlorides. Figure 3.4 provides the 
1HNMR spectra for amantadine (1) and 1a. The addition of 5 aromatic protons (6-8 ppm) confirms 




Figure 3.3: An example of mechanism used to couple various R groups to the aminoadamantane 
scaffold (benzoyl chloride and amantadine respectively in this example). 
 
Figure 3.4: Sample 1HNMR spectra for amine alkylation of amantadine (1) by benzoyl chloride to 
obtain 1a (in DMSO-d6). 
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3.1.2 Synthesis of aminobenzamide and aminobenzyl derivatives of amantadine, memantine 
and rimantadine 
The desired aminobenzamide and  aminobenzyl derivatives were synthesized by the 
reduction of 1d, f, g;  2d, e, f and 3d, e, f  to generate 1m, n, p; 2m, n, o and 3m, n, o . Figure 3.5 
provides the chemical structures of the synthesized derivatives. The chemistry procedures to 
synthesize the derivatives are provided in Chapter 6. 
 
 
Figure 3.5: The synthesized aminobenzamide and aminobenzyl derivative of adamantane.  
To obtain the desired final products carrying either an aminobenzamide or aminobenzyl 
substituents, the reduction of nitro functional group to amine was carried out using hydrazine 
hydrate (N2H4.H2O) as reducing agent. N2H4.H2O can form hydrogen (H
+) and nitrogen gas (N2) in 
presence of palladium (Pd/C) to facilitate the reduction process. Pd acts as the source of electrons 
and N2H4.H2O is the source of H
+, where in the first step nitro group is reduced to nitrosogroup. 
Hydroxylamine is generated in the second step via reductive addition of two H+ atoms to nitroso. 
In final step, amine is formed from hydroxylamine (Figure 3.6). Figure 3.7 shows the 1HNMR 
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spectra of desired amine compound 1n from its precursor nitro compound 1f. The addition of 2 
hydrogens at 5.5 ppm along with the shift in aromatic region confirms the formation of 1n.  





Figure 3.7: 1HNMR spectra for the reduction of nitro functional group on 1f to amine to obtain 1n 
(in DMSO-d6). 
 
3.1.3 Synthesis of azidobenzamide derivatives of amantadine, memantine and rimantadine 
The desired azidobenzamide derivatives were synthesized by nucleophilic substitution of 
bromide on 1i, k; 2i, k and 3i, k to azide to produce 1q, s; 2q, s and 3q, s. Figure 3.8 provides the 
chemical structures of the synthesized derivatives. The chemistry procedures to synthesize these 




Figure 3.8: The synthesized azidobenzamide derivatives.  
Synthesis of desired azide compounds from their precursor bromide compounds is a classic 
example of nucleophilic substitution where azide ion (N3) acts as a nucleophile to replace bromide 
substituent on the aromatic ring. Sodium azide is the source of azide ion in the reaction where 
sodium scavenge the bromide ion (Br-) to form sodium bromide (NaBr). The reaction proceeds in a 
single step where azide ion attacks the electron deficient carbon next to the bromine atom. (Figure 
3.9). The 1HNMR spectra of the desired azide compound 2s from its precursor bromide compound 
2k is shown in Figure 3.10. The significant shift in the aromatic regions along with mass 
spectroscopy confirms the formation of 2s.  
 
Figure 3.9: Sample 1HNMR spectra of nucleophilic substitution of bromide by azide to produce 




Figure 3.10: 1HNMR spectra of nucleophilic substitution of bromide by azide to produce the 
desired derivative 2s from 2k (2k in DMSO-d6 and 2s in CDCl3). 
3.2  Biological Assays  
3.2.1 Amyloid Aggregation Kinetics 
The biological activities of synthesized compounds will be evaluated using Aβ40 and Aβ42 
anti-aggregation assays. Aβ assay is a thioflavin T (ThT), based kinetic fluorescence method which 
is run at pH 7.4 at 37 °C. The fluorescence excitation and emission of ThT is monitored and the 
change in excitation-emission, due to conformational change of ThT, is detected upon interaction 
of ThT with β-sheet formation of Aβ oligomers and fibrils.147 The interactions between ThT and 
Aβ fibrils result in a linear fluorescence shift from 385-446 nm to 450-490 nm, allowing to quantify 
the aggregation of Aβ monomers in real time (Figure 3.11). Compounds with anti-aggregation 
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properties promote free ThT which is indicated by the lower relative fluorescence units (RFU) 
values whereas compounds with pro-aggregation properties result in higher RFU values in 
comparison with Aβ control. 







Figure 3.12: A typical ThT monitored A) Aβ40 aggregation plot, B) Aβ42 aggregation plot.   The 
lag phase only observed in Aβ40 aggregation and ends at the start of aggregation slope. The plateau 
phase is observed in both Aβ40/42 aggregation plot where the peptide is mainly in the fibril form.        
The following set of aggregation kinetics and imaging experiments were carried out on the 
synthesized adamantane derivatives:   
1- Self-induced Aβ40 aggregation kinetic assay for all derivatives 
2- Self-induced Aβ42 aggregation kinetic assay for selected derivatives with anti-aggregation 
properties toward Aβ40 
3- TEM imaging to study the morphology of Aβ 40/42 for derivatives with anti-aggregation 
properties toward both Aβ 40/42 
































3.2.2 Transmission Electron Microscopy (TEM) 
Transmission electron microscopy (TEM) is a common technique used in various fields to obtain 
high resolution images from a sample. In context of this research, the morphology of Aβ was studied 
at the conclusion of a 24 hour incubation period of the lead derivatives with Aβ 40. Derivatives with 
inhibitory properties against Aβ 40 decrease the density of Aβ fibrils compared to Aβ control. It 
also provides a quantitative method to further confirm the SAR data gathered from biological 
assays. The experimental setup is provided in chapter 6.  
 
Figure 3.13:  TEM imaging of : A) Aβ 40 fibrils, B) Aβ 42 fibrils. 
3.3 Conclusion 
The alkylation of primary of amantadine, memantine and rimantadine by benzoyl and benzyl 
series (Figure 28) were straightforward with relatively decent yields in general, however coupling 




success and low yields. The aminobenzamide and aminobenzyl derivatives (Figure 31) were 
synthesized with relative ease and high yields in general. Finally, the nucleophilic substitution of 
bromide by azide proved to be more challenging than initially anticipated with low yields and 
stability of the azido-substituted derivatives hindering the synthesis of the entire library. A total of 












4 Chapter 4: Results and Discussion 
4.1 Structure-Activity Relationship (SAR) studies 
The anti-aggregation potential of the synthesized derivatives were measured by the ThT based 
kinetic assay explained in the previous chapter (section 3.2). Test compounds were evaluated at 1, 
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5, 25 μM concentrations in triplicates in the presence of Aβ40/42 (5 μM). The obtained IC50 values 
were compared with the standard controls, orange G and resveratrol, and the adamantane scaffolds, 
1, 2 and 3. The obtained SAR data is divided into three sections based the three adamantane 
scaffolds. This chapter describes the SAR data acquired and discusses the ability of synthesized 
derivatives to prevent Aβ aggregation.  
4.1.1 Amantadine (1) based derivatives SAR   





Aβ40             Aβ42 
ClogPb 
Amantadine - N.A N.A 2.00 
1a Benzoyl P.A - 3.52 
1b Benzyl N.A - 4.17 
1c Acetophenone 4.3 >50 3.54 
1d 3-Nitrobenzoyl P.A - 3.70 
1e 3-Nitrobenzyl P.A - 3.91 
1f 4-Nitrobenzoyl P.A - 3.70 
1g 4-Nitrobenzyl P.A - 3.91 
1i 3-Bromobenzoyl P.A - 4.58 
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1j 3-Bromobenzyl P.A - 5.03 
1k 4-Bromobenzoyl P.A - 4.58 
1l 4-Bromobenzyl  P.A - 5.03 
1m 3-Aminobenzoyl N.A >50 2.61 
1n 4-Aminobenzoyl 2.9 >50 2.61 
1p 4-Aminobenzyl N.A N.A 2.94 
1q 3-Azidobenzoyl P.A - 4.22 
1s 4-Azidobenzoyl P.A - 4.22 
Orange G - 3.2 8.8 -0.63 
Resveratrol - 2.8 4.1 2.83 
 
aThe calculated IC50 values are the mean values of triplicate readings for two independent 
experiments. The values are based on the ThT-based fluorescence assay. N.A = Not Active (less 
than 10% inhibition), P.A = Promotes Aggregation. bThe ClogP values were determined using 




Figure 4.1: Summary of inhibition data for 17 amantadine (1) based derivatives on self-induced 
Aβ40 aggregation. N.A = Not Active, P.A = Promotes Aggregation.   
Surprisingly most of the amantadine based derivatives exhibited pro-aggregation activity 
toward Aβ40 as presented in Table 4.1. The unsubstituted 1a derivative promoted the aggregation 
of Aβ40 by 36% at 25 μM, however the 1b derivative did not exhibit any inhibition for Aβ40. 
Interestingly only compounds 1c and 1n exhibited anti-aggregation activity toward Aβ40 where 1c 
exhibited an IC50 value of 4.3 μM toward Aβ40 with similar potency compared to the reference 
agents orange G (3.2 μM) and resveratrol (2.8 μM). However it was not effective against Aβ42 
(IC50 > 50 μM) compared to the reference agents orange G (8.8 μM) and resveratrol (4.1 μM). The 
addition of electron withdrawing (EWG) nitro functional group at meta- (3) position on 1d 
promoted the aggregation of Aβ40 by more than 3 folds compared to 1a. A similar pattern was 
observed for 1e. Interestingly, moving the nitro group to para- (4) position in 1f exhibited pro-
aggregation activity at lower concentrations of 1 μM (60%) and 5 μM (31%). At 25 μM it was 
ineffective against Aβ40. Moving the nitro group to para- position on 1g yielded similar results 
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derivatives 1i, 1j, 1k and 1l regardless of meta- or para- positioning where the derivatives promoted 
the aggregation of Aβ40 up to 5 folds at all tested concentrations as illustrated in Figure 4.2 (kinetic 
data is provided for 1i as an example).   
 
Figure 4.2: ThT-based Aβ40 aggregation kinetic data at 37 °C, at pH 7.4, 24 h. Panels: (A) 
Resveratrol, (B) 1i. Results are expressed as average of two independent experiments (n =3). 
The addition of amine functional group on 1m, 1n and 1p yielded mixed inhibitory activity 
against Aβ40 aggregation. With amino group at meta-position in 1m and para-position in 1p, both 
derivatives failed to inhibit the aggregation of Aβ40 and Aβ42 at the tested concentrations. 
Compound 1n was identified as the most potent Aβ40 inhibitor in the amantadine based derivatives 
(IC50 = 2.9 μM) with similar activity as reference agents. This indicates that amine group enhances 
the Aβ40 inhibition at para- position compared to 1m and unsubstituted 1a. The effect of electron 
donating group (EDG) of azide was investigated in derivatives 1q and 1s. The presence of azide on 
meta- or para- position of 1q and 1s respectively promoted the aggregation of Aβ40 by 42% and 
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4.1.2 Top candidates from the amantadine (1) based derivatives           
 
Figure 4.3: Compounds with anti-Aβ40 activity in the amantadine based series.  
 
 
Figure 4.4: ThT-based Aβ40 aggregation kinetic data at 37 °C, at pH 7.4, 24 h. Panels: (A) 1c, 
(B) 1n. Results are expressed as average of two independent experiments (n =3). 
The aggregation kinetic data for derivative 1c (Figure 4.4 panel A) demonstrates that the 
compound inhibits the aggregation of Aβ40 at all tested concentrations. However its efficacy 
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5 and 25 μM concentrations respectively. At 1 μM, 1c was also able to delay the aggregation process 
by 1.5 fold, however it wasn’t able to shift the lag phase at higher concentrations. 
Similar pattern was observed with 1n, where 1n exhibited 66%, 41% and 22% inhibition at 
1, 5 and 25 μM concentrations respectively. At 1 μM, 1n showed superior anti-aggregation activity 
compared to reference agent resveratrol with 35% inhibition. However it was less potent at 5 and 
25 μM (52% and 81% respectively). 1n also delayed the aggregation process by 1.5 fold at all tested 















Figure 4.5: Docking of 1n in the Aβ dimer (PDB id: 2LMN) model.  
 
The binding mode of Aβ40 aggregation inhibitor 1n was investigated in the Aβ dimer model. 
The modeling study showed that the amantadine hydrophobic core was close to KLVFFA segment 
of the peptide to form two hydrophobic pi-alkyl interactions with Phe20 at 4.43 Å and 5.17 Å as 
shown in Figure 4.5. The aromatic ring of 1n was able to form a strong pi-sigma hydrophobic 
interaction with Ile32 at 2.86 Å. The amino group at the para- position was also able to form two 
relatively strong hydrogen bondings with ile32 at 4.21 Å and 4.60 Å respectively. The hydrogen 
bondings of 1n along with the other hydrophobic interactions stabilize the dimer structure and 
contribute to its superior anti-aggregation activity compared to 1c. 
Majority of the compounds in this series were promoting Aβ40 aggregation which proves 
that our hypothesis doesn’t hold true. It appears that the adamantane based derivatives might 
 58 
 
promote Aβ40 aggregation by acting as small molecule chaperones and change the conformation of 
Aβ40 which forces β-sheet formation and fibril assembly. This could be an advantage as Aβ fibrils 
are known to be less toxic compared to Aβ oligomers. In a hypothetical scenario, amantadine 
derivatives might in fact convert the more toxic Aβ oligomers into less toxic fibrils. The exact 
molecular mechanisms involved needs an in-depth study.   
 
4.1.4 Memantine (2) based derivatives SAR   




IC50 (µM) a 
Aβ40             Aβ42 
ClogPb 
Memantine - N.A N.A 3.0 
2a Benzoyl P.A - 4.56 
2b Benzyl P.A - 5.21 
2c Acetophenone P.A - 4.57 
2d 3-Nitrobenzoyl P.A - 4.73 
2e 3-Nitrobenzyl P.A - 4.95 
2f 4-Nitrobenzoyl P.A - 4.73 
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2g 4-Nitrobenzyl P.A - 4.95 
2i 3-Bromobenzoyl P.A - 5.62 
2j 3-Bromobenzyl 23.8 N.A 6.07 
2k 4-Bromobenzoyl P.A - 5.62 
2l 4-Bromobenzyl  1.8 >50 6.07 
2m 3-Aminobenzoyl 5.5 N.A 3.65 
2n 4-Aminobenzoyl 0.4 N.A 3.65 
2o 3-Aminobenzyl P.A - 3.98 
2q 3-Azidobenzoyl P.A - 5.26 
2s 4-Azidobenzoyl P.A - 5.26 
Orange G - 3.2 8.8 -0.63 
Resveratrol - 2.8 4.1 2.83 
 
aThe calculated IC50 values are the mean values of triplicate readings for two independent 
experiments. The values are based on the ThT-based fluorescence assay. n.a = not active, P.A = 
promotes aggregation. bThe ClogP values were determined using ChemBioDraw Ultra 14.0. 




Figure 4.6: Summary of inhibition data for 17 memantine (2) based derivatives against self-
induced Aβ 40. N.A = Not Active, P.A = Promotes Aggregation. 
 
Memantine based derivatives inhibitory activity against Aβ aggregation ranges from anti- 
to pro-aggregation as summarized by Table 4.2. The unsubstituted 2a, 2b and 2c derivatives 
promoted the aggregation of Aβ40 in a concentration dependent manner especially in case of 2a by 
2.5 folds. The addition of nitro substituent in 2d, 2e, 2f and 2g derivatives also promoted the 
aggregation of Aβ40 in a concentration dependent manner. This observation was further 
investigated and confirmed by molecular modeling studies of the derivatives where they de-
stabilized the Aβ40 dimer structure, facilitating the aggregation process.  
Interestingly unlike amantadine based derivatives, the addition of bromo in 2j and 2l 
exhibited inhibitory properties with IC50 values of 23.8 μM and 1.8 μM respectively. Compound 2l 
significantly more potent (13.2 folds) compared to 2j suggesting that the para- position of bromo 
compared to meta- position enhances the inhibitory activity. Compound 2l also exhibited superior 
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2.8 μM respectively). Surprisingly, both 2i and 2k promoted the aggregation at all tested 
concentrations. 
Compound 2n (IC50 = 0.4 μM) was identified as the most potent Aβ40 inhibitor in the 
memantine based derivatives with amino group at para- position, although it was not active against 
Aβ42. Moving the amino to meta- position diminished the inhibitory activity of 2m (IC50 = 5.5 μM) 
by more than 13 folds. The 2o, 2q and 2s derivatives promoted Aβ40 aggregation. None of the 
compounds in this series exhibited activity toward Aβ42. 
                     
4.1.5 Top candidates from the memantine (2) based derivatives 
 




Figure 4.8: ThT-based Aβ40 aggregation kinetic data at 37 °C, at pH 7.4, 24 h. Panels: (A) 2l, (B) 
2n. Results are expressed as average of two independent experiments (n =3). 
As illustrated by Figure 4.8, the 4-bromobenzyl derivative (2l) inhibited the aggregation of 
Aβ40 and showed superior inhibition of 67% at 1 μM compared to the both references orange G 
and resveratrol at 21% and 35%. However it was less potent at 5 μM and 25 μM concentrations 
with 21% and 9% inhibition, respectively. Both the reference compounds exhibited a concentration-
dependent inhibition against Aβ40 unlike 2l and 2n derivatives. Compound 2l was also able to shift 
the lag phase to the right even at highest tested concentration delaying the aggregation by 1.6 fold. 
The 4-aminobenzoyl derivative (2n) was even more potent than 2l, exhibiting superior 
inhibition at 1 μM and 5 μM with 76% and 67% inhibition and hindering the aggregation process 
by stabilizing the early formed intermediates as evident by Figure 4.8 (panel B). At 5 μM, it was 
more potent than orange G with 53% inhibition and resveratrol with slightly weaker inhibition at 
64%. Interestingly, at 25 μM 2n promoted the aggregation of Aβ40 by 17%.   
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4.1.6 Molecular modeling studies of the lead candidates (2l and 2n) 
 
Figure 4.9: Docking of 2n in the Aβ dimer (PDB id: 2LMN) model. 
The binding mode of 2n in Aβ dimer model demonstrates that its memantine core was 
oriented towards KLVFFA segment to form a relatively strong pi-alkyl hydrophobic interaction 
with Phe20 at 5.14 Å. One of the methyl groups attached to the core also forms a slightly weaker 
pi-alkyl hydrophobic interaction with Phe19 at 5.33 Å. The aromatic ring of 2n is close to oxygen 
on Leu34 to provide a strong pi-lone pair interaction at 2.94 Å. The amino group at the para- 
position is also close enough to oxygen on Val36 to form two hydrogen bondings at 3.17 Å and 
4.27 Å respectively. This observation is in agreement with the Aβ assay data confirming that 2n 




Figure 4.10: Docking of 2l in the Aβ dimer (PDB id: 2LMN) model. 
The binding mode of 2l with Aβ dimer model is provided in Figure 4.10. Similar to 2n, the 
memantine core is oriented towards KLVFAA segment, making two hydrophobic pi-alkyl 
interactions at 5.26 Å with Phe20 and at 4.92 Å with Phe19. The aromatic rings undergoes two 
hydrophobic pi-alkyl interactions at 5.50 Å with Ile32 and at 3.20 Å with Leu34. The bromo 
substituent at para- position is close to Val36 where it forms a hydrophobic interaction at 4.71 Å. 
Overall this derivative exhibited a number of hydrophobic interactions with the dimer structure 
allowing it to inhibit the aggregation of Aβ. 
The aggregation kinetics and modeling studies show that memantine based derivatives 
predominantly are capable of promoting Aβ40 aggregation. Molecular docking studies using Aβ 
dimer model shows that these compounds form a high energy complex with Aβ suggesting their 
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inability to stabilize the dimer assembly. However four compounds in this series (2j, 2l, 2m and 2n) 
were able to prevent Aβ40 aggregation with 2n identified as a potent inhibitor which was 8-fold 
more potent compared to orange G.  
  
 
4.1.7 Rimantadine (3) based derivatives SAR  




IC50 (µM) a 
Aβ40             Aβ42 
ClogPb 
Rimantadine - N.A N.A 3.90 
3a Benzoyl P.A - 5.49 
3b Benzyl P.A - 6.14 
3d 3-Nitrobenzoyl P.A - 5.66 
3e 3-Nitrobenzyl P.A - 5.88 
3f 4-Nitrobenzoyl P.A - 5.66 
3g 4-Nitrobenzyl P.A - 5.88 
3h 4-Nitroacetophenone N.A N.A 5.41 
3i 3-Bromobenzoyl P.A - 6.55 
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3j 3-Bromobenzyl P.A - 7.00 
3k 4-Bromobenzoyl P.A - 6.55 
3l 4-Bromobenzyl  P.A - 7.00 
3m 3-Aminobenzoyl 5.5 N.A 4.58 
3n 4-Aminobenzoyl 1.8 N.A 4.58 
3o 3-Aminobenzyl P.A - 4.91 
3p 3-Azidobenzoyl P.A - 6.19 
3s 4-Azidobenzoyl P.A - 6.19 
Orange G - 3.2 8.8 -0.63 
Resveratrol - 2.8 4.1 2.83 
 
aThe calculated IC50 values are the mean values of triplicate readings for two independent 
experiments. The values are based on the ThT-based fluorescence assay. N.A = Not Active, P.A = 
Promotes Aggregation. bThe ClogP values were determined using ChemBioDraw Ultra 14.0. 





Figure 4.11: Summary of inhibition data for 17 rimantadine (3) based derivatives against self-
induced Aβ40. N.A = Not Active, P.A = Promotes Aggregation. 
Rimantadine based derivatives generally promoted Aβ40 aggregation with derivatives 3m 
and 3n exhibiting aggregation inhibition at 5.5 and 1.8 μM as provided in Table 4.3. It is worth 
mentioning that none of the three derivatives (3h, 3m and 3n) that passed the initial screening 
with Aβ40, exhibited any activity for Aβ42. 
The unsubstituted benzoyl (3a) and benzyl (3b) derivatives promoted the aggregation of 
Aβ40 at all the concentrations, although 3b exhibited a much weaker pro-aggregation behavior at 
39% at the highest concentration compared to 3a at 200%. The 3- and 4-nitrobenzoyl derivatives 
3d and 3f respectively, yielded similar activity to the unsubstituted derivative (3a). The addition of 
nitro at meta- and para- position to benzyl derivatives 3e and 3g also proved to be detrimental to 
the inhibition of Aβ40. 
The 3- and 4-bromobenzoyl derivatives (3i and 3k) like other bromo substituted derivatives 
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pro-aggregation activity decreased as the concentration of the test compounds was increased from 
1 μM to 25 μM. Interestingly, both derivatives significantly reduced the lag phase, accelerating the 
aggregation of Aβ40. The 3j and 3l derivatives, 3- and 4-bromobenzyl, also promoted the 
aggregation of Aβ40 at all concentrations.  
The addition of amino substituent at the meta- and para- position on benzoyl yielded 3m 
and 3n derivatives. The 3m and 3n derivatives were identified as the lead compounds in the 
rimantadine series with IC50 values of 5.5 μM and 1.8 μM respectively for Aβ40. Compounds 3o, 
3p and 3s also promoted the aggregation of Aβ40 in the initial screening of the synthesized 
derivatives. None of the compounds in this series were able to prevent or promote Aβ40/42 
aggregation.  
4.1.8 Top candidates from the rimantadine (3) based derivatives 
 
 




Figure 4.13: ThT-based Aβ40 aggregation kinetic data at 37 °C, at pH 7.4, 24 h. Panels: (A) 3m, 
(B) 3n. Results are expressed as average of two independent experiments (n =3). 
The aggregation kinetic data of 3m and 3n derivatives is shown in Figure 4.13. The 3m 
derivative inhibits the aggregation of Aβ40 at the tested concentrations. Interestingly, 3m is the only 
derivative showing concentration dependent inhibition in the entire library. 3m exhibited inferior 
inhibition at 1, 5 and 25 μM (28%, 54% and 65%) compared to resveratrol (35%, 64% and 81%). 
This observation was also mirrored by the IC50 values of 3m, resveratrol and orange G at 5.5, 2.8 
and 3.2 μM respectively. The lead derivative from this series, 3n (IC50 = 1.8 μM) was ~ 1.5 fold 
more potent compared to resveratrol (IC50 = 2.8 μM). In this series none of the compounds exhibited 
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4.1.9 Molecular modeling studies of the lead candidates (3m and 3n) 
 
Figure 4.14: Docking of 3m in the Aβ dimer (PDB id: 2LMN) model.  
The binding mode of 3m in Aβ40 dimer model is shown in the Figure 4.14. The rimantadine 
core was oriented in the center of dimer structure, allowing it to form two pi-alkyl hydrophobic 
interactions with the opposite sides of the loop. The interaction was made with Phe20 at 5.06 Å and 
the second interaction was made with Ile32 at 5.32 Å. The benzoyl aromatic ring forms pi-alkyl 
hydrophobic interaction with Val36 at 5.43 Å. The amino group at para- position is close to oxygen 
on Leu34 resulting in formation of two hydrogen bondings at 3.99 Å and 4.83 Å forming a stable 





Figure 4.15: Docking of 3n in the Aβ dimer (PDB id: 2LMN) model.  
As illustrated in Figure 4.15, the rimantadine core of 3n is much closer to KLVFAA segment 
compared to 3m allowing it to form a much stronger pi-alkyl hydrophobic interaction with Phe20 
at 4.15 Å. Similarly, the benzoyl aromatic ring is positioned closer to Ile32, forming a strong pi-
alkyl hydrophobic interaction at 4.14 Å. As a result, the para- positioned amino group located closer 
to Leu34 compared to 3m, forming two hydrogen bondings with the back-bone of Leu34 at 2.90 Å 
and 4.61 Å. Overall this derivative exhibited a number of hydrophobic interactions with the dimer 





4.1.10 Transmission electron microscopy (TEM) data for compounds 1n, 2n and 3n 
The morphology of Aβ40 was investigated in the presence of the lead candidates from each 
series, compounds 1n, 2n and 3n. As illustrated in Figure 4.16, all the lead candidates were able to 
inhibit the aggregation of Aβ40 (Panels B, C and D for 1n, 2n and 3n respectively) compared to 
Aβ40 control (Panel A) and mirrored the obtained data from the ThT-based Aβ40 aggregation 
kinetic experiments (Figures 4.4, 4.8 and 4.13). The observation of Aβ40 oligomers further confirms 
the assay results where the lead compounds were able to stabilize the early formed Aβ40 
intermidiates and delay the aggregation process. 
 
                              
Figure 4.16: TEM assessment of Aβ40 morphalogy in presence and absence of lead compounds. 
Panels: (A) Aβ40 control, (B) Aβ40 incubated with 1n, (C) Aβ40 incubated with 2n, (D) Aβ40 





4.1.11 Promotion of Aβ40 aggregation by aminoadamantanes  
As discussed in Chapter 1 (section 1.7), developing Aβ inhibitors is one of the more 
favorable approaches in Aβ therapy. In recent years pro-aggregation approach has attracted 
considerable attention where by converting Aβ oligomers which is  the most toxic form of Aβ 
aggregates to less toxic Aβ fibrils,  can minimize the exposure of neuronal cells to Aβ oligomers 
and improve the cell viability as a result. Ideally, Aβ fibril specific antibodies can be used in 
combination with treatments capable of promoting the aggregation of Aβ to convert Aβ oligomers 
to mature fibrils and remove them by the antibodies, thereby reducing the Aβ load.  
 





5 Chapter 5: Conclusion and Future Work 
5.1 Conclusion 
A library of 48 aminoadamantane derivatives were designed, synthesized and characterized. 
They were evaluated for anti- Aβ activity against both Aβ40 and 42 aggregation. These experiments 
were conducted by ThT based fluorescence and TEM studies.  
The adamantane scaffolds (amantadine, memantine and rimantadine) was chosen as the 
templates in design and development of the library based on their therapeutic application in 
neurodegenerative disorders including AD, review of recent literatures and preliminary molecular 
modeling studies. The library was synthesized utilizing a number synthetic methods described in 
Chapter 3 with yields ranging from 9% to 92%. The biological screenings were accomplished using 
previously reported methods and optimized in-house to obtain SAR data. The molecular modeling 
were conducted to gain some insights into and validate the SAR data for anti-aggregation properties 
of the lead derivatives. The following table provides a summary of various parameters of the 
synthesized library:  
Table 5.1: Summary of various parameters of the synthesized aminoadamantane library.         
 Molecular weights (MWs) 241.2-361.1 g/mol 
 Partition Coefficients (ClogPs) 2.61-7.00 
 Aβ40 aggregation inhibition 0 -76% 
 Aβ40 IC50 0.4 – 23.8 μM 
 Aβ42 aggregation inhibition 0-15% 





In general, the majority of the synthesized derivatives (36 out of 48) were classified as Aβ40 
aggregation promoters. Only few derivatives exhibited inhibitory activity for Aβ40 with 2n 
memantine derivative (IC50 = 0.4 μM) identified as the most potent which was 8-fold more potent 
compared to orange G (IC50 = 3.2 μM) with  the other lead candidates exhibiting IC50 value ranging 
from 1.8 to 23.8 μM (chapter 4). Presence of amino group on the aromatic ring of the synthesized 
derivatives proved to be essential for superior inhibitory activity with the exception of 1c and 2l. 
The molecular modeling studies of the lead derivatives showed that the hydrophobic 
interactions of compounds with the KLVFFA segment is necessary to inhibit the aggregation of 
Aβ40. Formation of relatively strong interactions such as hydrogen bonding and hydrophobic with 
other regions of Aβ is necessary to stabilize the Aβ dimer structure and hinder the aggregation 
process. 
The SAR data acquired from biological screening of derivatives coupled with molecular 
modeling studies support the hypothesis that the aminoadamantane scaffold serves as a suitable 
template to design and develop potential treatments for AD.        
5.2 Future directions 
Based on the current SAR and biological evaluations the future studies regarding this project 
can be divided into two promising however opposite directions: 
 Further expansion of the library by modifying the structure of  lead derivatives to 
improve their biological profile as Aβ inhibitors. 
  Further exploring and developing pro-aggregation candidates as an alternative 
approach in treatment of AD as discussed in Chapter 1 and Chapter 4, section 4.1.11.  
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 In that regard, the memantine derivative 2d was identified as the lead Aβ40 promoter, which not 
only promoted the aggregation of Aβ40, it also dramatically reduced the lag phase at 25 μM (Figure 
5.1). As discussed in Chapter 1  and Chapter 4, pro-aggregation compounds can be used to minimize 
the exposure of neurons to toxic Aβ oligomers.    
 
Figure 5.1: ThT-based Aβ40 aggregation kinetic data of 2d at 37 °C, at pH 7.4, 24 h. Results are 
expressed as average of two independent experiments (n =3). 
Screening the library for other pathological aspects of AD such as cholinergic dysfunction, NMDA 
excitotoxicity and metal chelation can also be considered as the next steps in this project. In that 
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6 Chapter 6: Experimental 
6.1 General Information 
All necessary chemicals and reagents were obtained from commercial vendors (Acros Organics ®, 
Sigma-Aldrich ®, Alfa aesar ®, TCI ®) with a minimum purity of 95% and were used without 
further purification. Melting points were determined using a REACH Devices digital melting point 
apparatus and are uncorrected. 1H NMR (300 MHz) spectra were recorded on a Bruker ® Avance 
spectrometer using CDCl3 or DMSO-d6 as reference solvents. Coupling constants (J values) were 
recorded in hertz (Hz) and the following abbreviations were used to assign multiplicity of NMR 
signals: s = singlet, d = doublet, t = triplet, m = multiplet, br = broad.  
Compound purification was accomplished using Merck 230-400 mesh silica gel 60. All synthesized 
derivatives showed single spot on thin-layer chromatography (TLC) performed on Merck 60 F254 
silica gel plates (0.2 mm) using three different solvent systems (9:1 EtOAc: MeOH; 3:1 EtOAc: 
hexanes and 3:1 EtOAc: DCM) and spots were visualized with UV 254 nm. Compound purity was 
measured using an Agilent 6100 series single quad LCMS equipped with an Agilent 1.8 µm Zorbax 
Eclipse Plus C18 (2.1 x 50 mm) running 90:10 MeOH/IPA at a flow rate of 0.4 mL/min with 





6.2.1 General method to synthesize substitutedbenzamide derivatives of amantadine, 
memantine and rimantadine 1-, 2-, 3- (a, d, f, i, k): 
 
Scheme 6.1: General method to synthesize substitutedbenzamide derivatives 1-, 2- and 3-(a, d, f, i, 
k) 
0.300 g (1.6 mmol) of amantadine HCl, (1.4 mmol) or memantine HCl or (1.4 mmol) or 
rimantadine HCl, 0.163 mL (1.6 mmol) of  benzoyl chloride and 30 mg (0.16 mmol) CuI were 
added to 10 mL of MeOH. The reaction mixture was stirred for 12 h at room temperature in the 
presence of 0.45 mL (3.2 mmol) of TEA. The mixture was concentrated and diluted with 5 mL of 
distilled water, followed by three extractions (3 x 15 mL) at slightly acidic conditions (pH ~ 6) with 
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EtOAc and dried over MgSO4. Column chromatography was performed using EtOAc/MeOH (5:1) 
as solvent system to afford target compounds 1-, 2- and 3-(a, d, f, i, k). (59-80%Yield) 
 
6.2.2 General method to synthesize N-substitutedbenzyl derivatives of amantadine, 




Scheme 6.2: General method to synthesize N-substitutedbenzyl derivatives 1-, 2- and 3-(b, e, 
g, j, l)  
0.300 g (1.6 mmol) of amantadine HCl, (1.4 mmol) or memantine HCl or (1.4 mmol) 
rimantadine HCl, was added to 10 mL of n-BuOH and heated up to 80 °C. Then 0.45 mL (3.2 mmol) 
of TEA was added to quench HCl followed by the addition of 30 mg (0.16 mmol) of CuI and 0.16 
mL (1.6 mmol) of benzyl bromide. The reaction mixture was refluxed at 85 °C for 24 h. The reaction 
mixture was concentrated and diluted with 5 mL of distilled water, followed by three extractions (3 
x 15 mL) at slightly acidic conditions (pH ~ 6) with EtOAc and dried over MgSO4. The crude 
compound was purified by carrying out column chromatography using EtOAc/MeOH (5:1) as 
solvent system to afford compounds 1-,2-,3-(b, e, g, j, l). (42-75%Yield) 
 
6.2.3 General method to synthesize substitutedphenylethan-1-one derivatives of 
amantadine, memantine and rimantadine 1-, 2- and -3- (c, h): 
 
Scheme 6.3: General method to synthesize phenylethan-1-one derivatives 1-, 2- and 3- (c , h). 
 
0.500 g (2.7 mmol) of amantadine HCl (2.3 mmol) or memantine HCl or (2.3 mmol) 
rimantadine HCl and 0.53 g (2.7 mmol) of 2-bromoacetophenone were added to 10 mL of 
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ACN/MeOH (9:1) solvent system. The reaction mixture was refluxed at 75 °C for 24 hours in the 
presence of 0.74 mL (5.3 mmol) of TEA and 51 mg (0.27 mmol) of CuI. The mixture was 
concentrated and diluted with 5 mL of distilled water, followed by three extractions (3 x 15 mL) at 
slightly acidic conditions (pH ~ 6) with EtOAc and dried over MgSO4. Colum chromatography was 
carried out using DCM/MeOH (9:1) solvent system to afford the target compounds 1-c,2-c,3-h,. (9-
16%Yield). 
 
6.2.4 General method of nitro reduction to synthesize aminobenzamide derivatives of 
amantadine, memantine and rimantadine 1-, 2- and 3- (m, n, o, p): 
 
Scheme 6.4: General method of nitro reduction to synthesize aminobenzamide derivatives 1-,2-,3-
(m, n, o, p) 
0.300 g (1.0 mmol) of compound 1f was dissolved in 20 mL of EtOH. 110 mg (0.09 mmol) 
of 10% Pd/C and sufficient molecular sieve were added to the reaction mixture on ice bath. 0.096 g 
(0.093 mL) (2.99 mmol) of N2H4.H2O (50%) was slowly added to the reaction mixture while 
stirring. The reaction mixture was then refluxed for 2 hours at 85 C, then filtered to remove Pd/C 
and molecular sieves, was concentrated and diluted with 5 mL of distilled water, followed by three 
extractions (3 x 15 mL) with EtOAc and dried over MgSO4. Column chromatography was carried 






6.2.5 General method to synthesize azidobenzamide derivatives of amantadine, memantine 
and rimantadine 1-, 2- and 3- (q, s): 
 
 
Scheme 6.5: General method of conversion of bromobenzamides to azidobenzamides. 
0.2 g (0.6 mmol) of corresponding bromide precursor of 1-,2-,3- (i, k) was dissolved in 20 mL of 
degassed mixture of water/EtOH (7:3). Then 78 mg (1.2 mmol) of NaN3, 11 mg (0.06 mmol) of CuI 
and 0.2 mL (0.18 mmol) of N,N-dimethylethylenediamine was added. Then the reaction mixture 
was refluxed at 120˚C for 4 h under an argon atmosphere. The mixture was concentrated and diluted 
with 5 mL of distilled water, followed by three extractions (3 x 20 mL) with ether and dried over 
MgSO4. Column chromatography was carried out using DCM/MeOH (5:1) solvent system to afford 
the target compounds 1-,2-,3-,. (23-45%Yield).  
 
6.2.6 1H NMR data for amantadine derivatives 1a-l 
Amantadine HCl: 1H NMR (300 MHz, DMSO-d6) δ 7.90 (s, 3H), δ 2.05 (s, 3H), δ 1.75 (d, J = 2.8 




N-(Adamantan-1-yl)benzamide (1a): Yield: 0.24 g, 59%; Mp: 146-149°C. The product was 
obtained as a yellow solid and was purified using EtOAc/MeOH (5:1).  1H NMR (300 MHz, DMSO-
d6) δ 7.74 (dd, J = 7.9, 4.4 Hz, 2H), δ 7.57 (d, J = 4.4 Hz, 1H), δ 7.42 – 7.36 (m, 3H), δ 2.04 (d, J = 
4.5 Hz, 9H), δ 1.63 (t, J = 3.3 Hz, 6H). C17H21NO. Purity: 99% 
 
N-Benzyladamantan-1-amine (1b): Yield: 0.24 g, 62%; Mp: 188-191°C. The product was 
obtained as a dark yellow solid and was purified using EtOAc/MeOH (5:1).1H NMR (300 MHz, 
DMSO-d6) δ 8.59 (br, 1H), δ 7.50 – 7.37 (m, 5H), δ 4.07 (s, 2H), δ 2.13 (s, 2H), δ 1.93 – 1.88 (m, 
6H), δ 1.73 – 1.57 (m, 7H). C17H23N. Purity:99% 
 
2-((Adamantan-1-yl)amino)-1-phenylethan-1-one (1c): Yield: 0.07 g, 9%; Mp: 172-175°C. The 
product was obtained as a dark brown solid and was purified using DCM/MeOH (9:1). 1H NMR 
(300 MHz, DMSO-d6) δ 8.42 (s, 1H), δ 8.02 – 7.97 (m, 2H), δ 7.67 – 7.62 (m, 1H), δ 7.52 (dd, J = 
8.2, 6.9 Hz, 2H), δ 4.79 (s, 2H), δ 2.05 (s, 2H), δ 1.88 (s, 7H), δ 1.61 (s, 6H). C18H23NO. Purity: 
99% 
 
N-(Adamantan-1-yl)-3-nitrobenzamide (1d): Yield: 0.2 g, 42%; Mp: 163-166°C. The product 
was obtained as a light yellow solid and was purified using EtOAc/MeOH (5:1). 1H NMR (300 
MHz, DMSO-d6) δ 8.56 (d, J = 2.1 Hz, 1H), δ 8.31 (d, J = 8.1 Hz, 1H), δ 8.19 (d, J = 7.8 Hz, 1H), 
δ 8.01 (s, 1H), δ 7.70 (t, J = 8.0 Hz, 1H), δ 2.06 (s, 9H), 1.64 (s, 6H). C17H20N2O3 . Purity:99% 
 
N-(3-Nitrobenzyl)adamantan-1-amine (1e): Yield: 0.21 g, 28%; Mp: 178-180°C. The product 
was obtained as a  brown solid and was purified using EtOAc/MeOH (5:1). 1H NMR (300 MHz, 
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DMSO-d6) δ 9.08 (s, 1H), δ 8.42 (s, 1H), δ 8.18 (d, J = 8.6 Hz, 1H), δ 7.96 (d, J = 7.6 Hz, 1H), δ 
7.67 (t, J = 8.0 Hz, 1H), δ 4.14 (s, 2H), δ 2.10 (s, 2H), δ 1.95 – 1.80 (m, 6H), δ 1.61 (d, J = 10.7 Hz, 
6H), δ 1.20 (s, 1H). C17H22N2O2 . Purity:95% 
 
N-(Adamantan-1-yl)-4-nitrobenzamide (1f): Yield: 0.36 g, 75%; Mp: 180-182°C. The product 
was obtained as a white solid and was purified using EtOAc/MeOH (5:1). 1H NMR (300 MHz, 
DMSO-d6) δ 8.24 (dd, J = 8.8, 2.8 Hz, 2H), δ 8.02 – 7.91 (m, 3H), δ 2.05 (d, J = 3.0 Hz, 9H), δ 1.63 
(d, J = 3.6 Hz, 6H). C17H20N2O3 . Purity:96.7% 
 
N-(Adamantan-1-yl)-3-bromobenzamide (1i): Yield: 0.41 g, 78%; Mp: 157-159°C. The product 
was obtained as a light yellow solid and was purified using EtOAc/MeOH (5:1). 1H NMR (300 
MHz, DMSO-d6) δ 7.92 (t, J = 1.8 Hz, 1H), δ 7.73 (s, 2H), δ 7.66 (d, J = 8.0 Hz, 1H), δ 7.36 (t, J = 
7.8 Hz, 1H), δ 2.03 (s, 9H), δ 1.62 (s, 6H). C17H20BrNO . Purity:98% 
 
N-(3-Bromobenzyl)adamantan-1-amine (1j): Yield: 0.29 g, 66%; Mp: >250°C. The product was 
obtained as a light brown solid and was purified using EtOAc/MeOH (5:1). 1H NMR (300 MHz, 
DMSO-d6) δ 9.29 (br, 1H), δ 7.89 (s, 1H), δ 7.64 – 7.56 (m, 2H), δ 7.36 (t, J = 6.6 Hz, 1H), δ 4.06 
(s, 2H), δ 2.12 (s, 3H), δ 1.97 (s, 6H), δ 1.63 (q, J = 12.5 Hz, 6H). C17H22BrN . Purity:98.6% 
 
N-(Adamantan-1-yl)-4-bromobenzamide (1k): Yield: 0.32 g, 59%; Mp: 178-180°C. The product 
was obtained as a white solid and was purified using EtOAc/MeOH (5:1). 1H NMR (300 MHz, 
DMSO-d6) δ 7.68 (t, J = 8.8 Hz, 3H), δ 7.59 (d, J = 8.2 Hz, 2H), δ 2.03 (s, 9H), δ 1.62 (s, 6H). 




N-(4-Bromobenzyl)adamantan-1-amine (1l): Yield: 0.34 g, 43%; Mp: >250°C.  The product was 
obtained as a  brown solid and was purified using EtOAc/MeOH (5:1). 1H NMR (300 MHz, 
Chloroform-d) δ 7.43 (t, J = 7.0 Hz, 4H), δ 3.80 (s, 2H), δ 1.86 (d, J = 2.9 Hz, 9H), δ 1.63 (d, J = 
4.5 Hz, 6H). C17H22BrN . Purity:99% 
 
N-(Adamantan-1-yl)-3-aminobenzamide (1m): Yield: 0.16 g, 60%; Mp: 163-166°C. The product 
was obtained as a dark brown solid and was purified using hexane/acetone (5:1). 1H NMR (300 
MHz, DMSO-d6) δ 7.26 (s, 1H), δ 6.99 (t, J = 7.8 Hz, 1H), δ 6.88 (s, 1H), δ 6.82 (d, J = 7.6 Hz, 
1H), δ 6.61 (d, J = 7.8 Hz, 1H), δ 5.12 (s, 2H), δ 2.01 (s, 9H), δ 1.62 (s, 6H). C17H22N2O . Purity:99% 
 
N-(Adamantan-1-yl)-4-aminobenzamide (1n): Yield: 0.2 g, 74%; Mp: 171-172°C. The product 
was obtained as a light brown solid and was purified using hexane/acetone (5:1). 1H NMR (300 
MHz, DMSO-d6) δ 7.51 (d, J = 8.3 Hz, 2H), δ 7.01 (d, J = 7.9 Hz, 1H), δ 6.49 (t, J = 7.9 Hz, 2H), 
δ 5.50 (d, J = 7.3 Hz, 2H), δ 2.02 (d, J = 7.1 Hz, 9H), δ 1.63 (d, J = 7.7 Hz, 5H), δ 1.22 (d, J = 7.7 
Hz, 1H). C17H22N2O . Purity:99% 
 
N-(4-Aminobenzyl)adamantan-1-amine (1p): Yield: 0.12 g, 46%; Mp: 219-221°C. The product 
was obtained as a dark brown solid and was purified using hexane/acetone (5:1). 1H NMR (300 
MHz, DMSO-d6) δ 8.44 (s, 1H), δ 8.26 (d, J = 8.4 Hz, 1H), δ 8.15 (d, J = 8.3 Hz, 2H), δ 7.99 (d, J 
= 8.3 Hz, 1H), δ 7.65 (d, J = 8.3 Hz, 2H), δ 3.88 (s, 2H), δ 2.01 (s, 3H), δ 1.57 (d, J = 8.4 Hz, 9H), 




6.2.7 1H NMR data for memantine derivatives 2a-l 
Memantine HCl: 1H NMR (300 MHz, DMSO-d6) δ 7.85 (s, 3H), δ 2.12 (s, 1H), δ 1.58 (d, J = 3.1 
Hz, 2H), δ 1.47 – 1.31 (m, 4H), δ 1.26 (s, 4H), δ 1.09 (q, J = 12.7 Hz, 2H), δ 0.82 (s, 6H).  
 
N-(3,5-Dimethyladamantan-1-yl)benzamide (2a): Yield: 0.29 g, 73%; Mp: 94-97°C. The product 
was obtained as a yellow solid and was purified using EtOAc/MeOH (5:1). 1H NMR (300 MHz, 
DMSO-d6) δ 7.79 – 7.68 (m, 2H), δ 7.60 (d, J = 4.8 Hz, 1H), δ 7.47 – 7.35 (m, 3H), δ 2.12 – 2.07 
(m, 1H), δ 1.88 (t, J = 4.0 Hz, 2H), δ 1.70 (t, J = 4.3 Hz, 4H), δ 1.39 – 1.18 (m, 4H), δ 1.12 (d, J = 
4.8 Hz, 2H), δ 0.82 (d, J = 4.7 Hz, 6H). C19H25NO . Purity:98% 
 
N-Benzyl-3,5-dimethyladamantan-1-amine (2b): Yield: 0.20 g, 55%; Mp: 190-192°C.  The 
product was obtained as a dark brown/red solid and was purified using EtOAc/MeOH (5:1). 1H 
NMR (300 MHz, DMSO-d6) δ 8.57 (s, 1H), δ 7.51 – 7.38 (m, 5H), δ 4.10 (d, J = 12.8 Hz, 2H), δ 
2.20 (s, 1H), δ 1.75 (d, J = 3.2 Hz, 2H), δ 1.57 (s, 4H), δ 1.31 (d, J = 2.9 Hz, 4H), δ 1.15 (d, J = 7.6 
Hz, 2H), δ 0.87 (s, 6H). C19H27N . Purity:97% 
 
2-((3,5-Dimethyladamantan-1-yl)amino)-1-phenylethan-1-one (2c): Yield: 0.08 g, 11%; Mp: 
158-160°C. The product was obtained as a dark orange solid and was purified using DCM/MeOH 
(9:1). 1H NMR (300 MHz, DMSO-d6) δ 8.41 (s, 1H), δ 8.00 (d, J = 7.5 Hz, 2H), δ 7.64 (t, J = 7.3 
Hz, 1H), δ 7.52 (t, J = 7.6 Hz, 2H), δ 4.78 (s, 2H), δ 2.12 (s, 1H), δ 1.73 (s, 2H), δ 1.53 (s, 4H), δ 




N-(3,5-Dimethyladamantan-1-yl)-3-nitrobenzamide (2d): Yield: 0.34 g, 71%; Mp: 106-109°C.  
The product was obtained as a light orange solid and was purified using EtOAc/MeOH (5:1). 1H 
NMR (300 MHz, DMSO-d6) δ 8.58 (br, 1H), δ 8.31 (d, J = 8.0 Hz, 1H), δ 8.24 – 8.14 (m, 1H), δ 
8.04 (s, 1H), δ 7.76 – 7.64 (m, 1H), δ 2.09 (q, J = 10.1 Hz, 1H), δ 1.90 (d, J = 9.5 Hz, 2H), δ 1.71 
(q, J = 11.9 Hz, 4H), δ 1.41 – 1.20 (m, 4H), δ 1.12 (s, 2H), δ 0.82 (s, 6H). C19H24N2O3 . Purity:95.3% 
 
3,5-Dimethyl-N-(3-nitrobenzyl)adamantan-1-amine (2e): Yield: 0.31 g, 42%; Mp: 144-147°C.  
The product was obtained as a  brown solid and was purified using EtOAc/MeOH (5:1). 1H NMR 
(300 MHz, DMSO-d6) δ 8.37 (s, 1H), δ 8.14 (d, J = 7.8 Hz, 1H), δ 7.90 (s, 1H), δ 7.63 (t, J = 7.9 
Hz, 1H), δ 4.03 (s, 2H), δ 2.13 (s, 1H), δ 1.63 (s, 2H), δ 1.45 (s, 4H), δ 1.35 – 1.12 (m, 4H), δ 1.10 
(d, J = 4.6 Hz, 2H), δ 0.83 (s, 6H). C19H26N2O2 . Purity:96.1% 
 
N-(3,5-Dimethyladamantan-1-yl)-4-nitrobenzamide (2f): Yield: 0.37 g, 49%; Mp: 164-166°C.  
The product was obtained as a light brown solid and was purified using EtOAc/MeOH (5:1). 1H 
NMR (300 MHz, DMSO-d6) δ 8.24 (d, J = 6.8 Hz, 2H), δ 7.95 (d, J = 6.8 Hz, 2H), δ 2.09 (d, J = 
9.7 Hz, 1H), δ 1.88 (s, 2H), δ 1.78 – 1.62 (m, 4H), δ 1.29 (q, J = 12.0 Hz, 4H), δ 1.12 (s, 2H), δ 0.82 
(s, 6H). C19H24N2O3 . Purity:96.6% 
 
3-Bromo-N-(3,5-dimethyladamantan-1-yl)benzamide (2i): Yield: 0.48 g, 68%; Mp: 110-112°C. 
The product was obtained as a dark yellow/orange solid and was purified using EtOAc/MeOH 
(5:1).1H NMR (300 MHz, DMSO-d6) δ 7.94 (d, J = 1.8 Hz, 1H), δ 7.74 (d, J = 7.6 Hz, 2H), δ 7.70 
– 7.60 (m, 1H), δ 7.35 (t, J = 7.9 Hz, 1H), δ 2.08 (d, J = 3.3 Hz, 1H), δ 1.87 (d, J = 3.1 Hz, 2H), δ 
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1.77 – 1.59 (m, 4H), δ 1.38 – 1.19 (m, 4H), δ 1.10 (s, 2H), δ 0.81 (s, 6H). C19H24BrNO . Purity: 
97% 
 
N-(3-Bromobenzyl)-3,5-dimethyladamantan-1-amine (2j): Yield: 0.19 g, 42%; Mp: 135-137°C.  
The product was obtained as a dark yellow solid and was purified using EtOAc/MeOH (5:1).  1H 
NMR (300 MHz, DMSO-d6) δ 7.52 (d, J = 1.9 Hz, 1H), δ 7.34 (dd, J = 7.7, 1.9 Hz, 1H), δ 7.29 (d, 
J = 7.6 Hz, 1H), δ 7.20 (t, J = 7.7 Hz, 1H), δ 3.64 (s, 2H), δ 2.04 (d, J = 3.4 Hz, 1H), δ 1.42 (d, J = 
3.1 Hz, 2H), δ 1.30 – 1.16 (m, 8H), δ 1.05 (s, 2H), δ 0.79 (s, 6H). C19H26BrN . Purity:95.2% 
 
4-Bromo-N-(3,5-dimethyladamantan-1-yl)benzamide (2k): Yield: 0.38 g, 64%; Mp: 127-130°C. 
The product was obtained as a light yellow solid and was purified using EtOAc/MeOH (5:1). 1H 
NMR (300 MHz, DMSO-d6) δ 7.70 (d, J = 8.6 Hz, 3H), δ 7.64 – 7.54 (m, 2H), δ 2.09 (s, 1H), δ 
1.86 (d, J = 3.1 low Hz, 2H), δ 1.76 – 1.60 (m, 4H), δ 1.38 – 1.18 (m, 4H), δ 1.11 (s, 2H), δ 0.81 (s, 
6H). C19H24BrNO . Purity: 99% 
N-(4-Bromobenzyl)-3,5-dimethyladamantan-1-amine (2l): Yield: 0.53 g, 66%; Mp: 182-185°C. 
The product was obtained as a light yellow solid and was purified using EtOAc/MeOH (5:1). 1H 
NMR (300 MHz, DMSO-d6) δ 9.11 (s, 1H), δ 7.66 – 7.56 (m, 2H), δ 7.53 (d, J = 8.5 Hz, 2H), δ 
4.03 (s, 2H), δ 2.18 (s, 1H), δ 1.78 (d, J = 3.1 Hz, 2H), δ 1.60 (t, J = 8.1 Hz, 4H), δ 1.29 (d, J = 3.0 
Hz, 4H), δ 1.22 – 1.04 (m, 2H), δ 0.85 (s, 6H). C19H26BrN . Purity: 99% 
 
3-Amino-N-(3,5-dimethyladamantan-1-yl)benzamide (2m): Yield: 0.25 g, 92%; Mp: 128-
130°C.  The product was obtained as a red solid and was purified using hexane/acetone (5:1).   1H 
NMR (300 MHz, DMSO-d6) δ 7.28 (s, 1H), δ 6.99 (t, J = 7.8, 1H), δ 6.92 – 6.86 (m, 1H), δ 6.82 (d, 
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J = 7.3 Hz, 1H), δ 6.66 – 6.55 (m, 1H), δ 5.11 (s, 2H), δ 2.11 – 2.02 (m, 1H), δ 1.84 (d, J = 3.2 Hz, 
2H), δ 1.66 (s, 4H), δ 1.26 (dd, J = 19.5, 8.5 Hz, 4H), δ 1.10 (s, 2H), δ 0.80 (s, 6H). C19H26N2O . 
Purity: 99.6% 
 
4-Amino-N-(3,5-dimethyladamantan-1-yl)benzamide (2n): Yield: 0.15 g, 56%; Mp: 90-92°C. 
The product was obtained as a dark orange solid and was purified using hexane/acetone (5:1).  1H 
NMR (300 MHz, DMSO-d6) δ 7.48 (d, J = 8.2 Hz, 2H), δ 7.04 (s, 1H) , δ 6.46 (d, J = 8.3 Hz, 2H), 
δ 5.48 (s, 2H), δ 2.11 – 1.99 (m, 1H), δ 1.84 (d, J = 10.1 Hz, 2H), δ 1.67 (t, J = 8.5 Hz, 4H), δ 1.33 
– 1.21 (m, 4H), δ 1.09 (s, 2H), δ 0.80 (s, 6H). C19H26N2O . Purity:99% 
 
N-(3-Aminobenzyl)-3,5-dimethyladamantan-1-amine (2o): Yield: 0.1 g, 40%; Mp: 219-221°C. 
The product was obtained as a dark brown solid and was purified using hexane/acetone (5:1).  1H 
NMR (300 MHz, CDCl3) δ 6.97 (t, J = 7.7 Hz, 1H), δ 6.57 (d, J = 7.3 Hz, 2H), δ 6.48 (d, J = 8.0 
Hz, 2H), δ 5.09 (s, 2H), δ 3.72 (s, 2H), δ 2.12 (s, 1H), δ 1.64 (s, 2H), δ 1.50 – 1.37 (m, 4H), δ 1.27 
(s, 4H), δ 1.10 (s, 2H), δ 0.83 (d, J = 2.9 Hz, 6H). C19H28N2 . Purity:96.6% 
 
4-Azido-N-(3,5-dimethyladamantan-1-yl)benzamide (2s): Yield: 0.08 g, 43%; Mp: 142-145°C.  
The product was obtained as a beige solid and was purified using DCM/MeOH (5:1). 1H NMR (300 
MHz, CDCl3 ) δ 7.53 (d, J = 8.3 Hz, 2H), δ 6.63 (d, J = 8.3 Hz, 2H), δ 5.69 (s, 1H), δ 1.97 – 1.90 
(m, 2H), δ 1.75 (s, 4H), δ 1.45 – 1.26 (m, 4H), δ 1.16 (t, J = 10.5 Hz, 2H), δ 0.90 – 0.83 (m, 6H). 





6.2.8 1H NMR data for rimantadine derivatives 3a-l 
Rimantadine HCl: 1H NMR (300 MHz, DMSO-d6) δ 7.61 (s, 3H), δ 2.74 (q, J = 7.0 Hz, 1H), δ 
1.94 (s, 3H), δ 1.66 – 1.46 (m, 12H), δ 1.06 (d, J = 6.8 Hz, 3H).  
 
N-(1-(1-Adamantan-1-yl)ethyl)benzamide (3a): Yield: 0.31 g, 76%; Mp: 178-180°C.  The 
product was obtained as a light yellow/brown solid and was purified using EtOAc/MeOH (5:1). 1H 
NMR (300 MHz, DMSO-d6) δ 7.89 (d, J = 9 Hz, 1H), δ 7.83 – 7.76 (m, 2H), δ 7.52 – 7.35 (m, 3H), 
δ 3.78 (d, J = 7.3 Hz, 1H), δ 1.91 (s, 3H), δ 1.67– 1.45 (m, 12H), δ 1.02 (d, J = 7.0 Hz, 3H). 
C19H25NO . Purity:96% 
 
1-(Adamantan-1-yl)-N-benzylethan-1-amine (3b): Yield: 0.21 g, 57%; Mp: 170-172°C. The 
product was obtained as a dark brown solid and was purified using EtOAc/MeOH (5:1). 1H NMR 
(300 MHz, DMSO-d6) δ 7.47 (d, J = 7.2 Hz, 2H), δ 7.41 – 7.30 (m, 3H), δ 4.04 (d, J = 7.2 Hz, 2H), 
δ 2.26 (s, 1H), δ 1.95 – 1.86 (m, 3H), δ 1.67 – 1.53 (m, 10H), δ 1.31 (d, J = 12.0 Hz, 3H), δ 1.06 (d, 
J = 6.8 Hz, 3H). C19H27N . Purity:98.1% 
 
N-(1-(Adamantan-1-yl)ethyl)-3-nitrobenzamide (3d): Yield: 0.60 g, 80%; Mp: 160-162°C.  The 
product was obtained as a light brown solid and was purified using EtOAc/MeOH (5:1). 1H NMR 
(300 MHz, DMSO-d6) δ 8.63 (t, J = 1.9 Hz, 1H), δ 8.39 – 8.21 (m, 3H), δ 7.73 (t, J = 8.0 Hz, 1H), 
δ 3.89 – 3.72 (m, 1H), δ 1.91 (s, 3H), δ 1.68 – 1.40 (m, 12H), δ 1.04 (d, J = 7.0 Hz, 3H). C19H24N2O3 
. Purity:99% 
 
1-(Adamantan-1-yl)-N-(4-nitrobenzyl)ethan-1-amine (3e): Yield: 0.50 g, 68%; Mp: 184-186°C. 
The product was obtained as a dark brown solid and was purified using EtOAc/MeOH (5:1).  1H 
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NMR (300 MHz, DMSO-d6) δ 8.21 (br, 1H), 8.04 (dd, J = 8.2, 2.3 Hz, 2H), δ 7.77 (d, J = 7.6 Hz, 
1H), δ 7.56 (t, J = 7.9 Hz, 1H), δ 3.96 – 3.64 (m, 2H), δ 1.98 – 1.85 (m, 5H), δ 1.59 (q, J = 10.9 Hz, 
10H), δ 1.45 – 1.34 (d, 2H), δ 0.88 (d, J = 6.4 Hz, 3H). C19H26N2O2 . Purity:95.1% 
 
N-(1-(Adamantan-1-yl)ethyl)-4-nitrobenzamide (3f): Yield: 0.49 g, 66%; Mp: 169-170°C. The 
product was obtained as a light brown solid and was purified using EtOAc/MeOH (5:1). 1H NMR 
(300 MHz, DMSO-d6) δ 8.26 (d, J = 9 Hz, 2H), δ 8.03 (d, J = 9 Hz, 2H), δ 3.79 (dd, J = 9.2, 6.8 
Hz, 1H), δ 1.91 (s, 3H), δ 1.65 – 1.45 (m, 12H), δ 1.03 (d, J = 7.1 Hz, 3H). C19H24N2O3 . 
Purity:94.8% 
 
1-(Adamantan-1-yl)-N-(4-nitrobenzyl)ethan-1-amine (3g): Yield: 0.41 g, 56%; Mp: 194-196°C. 
The product was obtained as a  brown solid and was purified using EtOAc/MeOH (5:1). 1H NMR 
(300 MHz, DMSO-d6) δ 8.22 – 8.09 (m, 2H), δ 7.60 (d, J = 8.4 Hz, 2H), δ 3.94 – 3.66 (m, 2H), δ 
1.94 – 1.88 (m, 4H), δ 1.65 – 1.51 (m, 10H), δ 1.45 – 1.35 (m, 3H), δ 0.87 (d, J = 6.5 Hz, 3H). 
C19H26N2O2 . Purity:95.3%  
 
2-((1-(Adamantan-1-yl)ethyl)amino)-1-(4-nitrophenyl)ethan-1-one (3h): Yield: 0.16 g, 33%; 
Mp: 161-164°C. The product was obtained as an orange solid and was purified using DCM/MeOH 
(9:1). 1H NMR (300 MHz, CDCl3) δ 8.67 (d, J = 8.9 Hz, 2H), δ 8.35 (d, J = 8.5 Hz, 2H), δ 5.86 (s, 
2H), δ 3.90 (d, J = 7.2 Hz, 1H), δ 3.15 – 3.12 (m, 1H), δ 1.63 (s, 5H), δ 1.44 (q, J = 7.3 Hz, 13H). 




N-(1-(Adamantan-1-yl)ethyl)-3-bromobenzamide (3i): Yield: 0.30 g, 78%; Mp: 170-172°C.  The 
product was obtained as a beige solid and was purified using EtOAc/MeOH (5:1).  1H NMR (300 
MHz, DMSO-d6) δ 8.01 (d, J = 8.6 Hz, 2H), δ 7.81 (d, J = 7.8 Hz, 1H), δ 7.68 (d, J = 7.8 Hz, 1H), 
δ 7.39 (t, J = 7.9 Hz, 1H), δ 3.77 (p, J = 7.3 Hz, 1H), δ 1.91 (s, 3H), δ 1.64 – 1.55 (m, 12H), δ 1.02 
(d, J = 6.9 Hz, 3H). C19H24BrNO . Purity: 96.3% 
 
N-(1-(Adamantan-1-yl)ethyl)-4-bromobenzamide (3k): Yield: 0.25 g, 65%; Mp: 201-203°C. The 
product was obtained as a beige solid and was purified using EtOAc/MeOH (5:1).  1H NMR (300 
MHz, DMSO-d6) δ 7.97 (d, J = 9 Hz, 1H), δ 7.76 (d, J = 8.2 Hz, 2H), δ 7.63 (d, J = 8.2 Hz, 2H), δ 
3.76 (d, J = 6.9 Hz, 1H), δ 1.90 (s, 3H), δ 1.65 – 1.55 (m, 12H), δ 1.01 (d, J = 6.9 Hz, 3H). 
C19H24BrNO . Purity: 96.5% 
 
1-(Adamantan-1-yl)-N-(4-bromobenzyl)ethan-1-amine (3l): Yield: 0.45 g, 56%; Mp: 188-
190°C. The product was obtained as a dark brown solid and was purified using EtOAc/MeOH (5:1). 
1H NMR (300 MHz, DMSO-d6) δ 7.69 – 7.57 (m, 1H), δ 7.44 (d, J = 8.3 Hz, 2H), δ 7.27 (d, J = 8.3 
Hz, 2H), δ 3.81 – 3.45 (m, 2H), δ 2.79 (q, J = 6.7 Hz, 1H), δ 1.97 – 1.85  (m, 3H), δ 1.67 – 1.44 (m, 
10H), δ 1.36 (dq, J = 12.2, 2.6 Hz, 2H), δ 0.85 (d, J = 6.5 Hz, 3H). C19H26BrN . Purity:94.8% 
 
N-(1-(Adamantan-1-yl)ethyl)-3-aminobenzamide (3m): Yield: 0.21 g, 77%; Mp: 128-130°C.  
The product was obtained as a light brown solid and was purified using hexane/acetone (5:1).   1H 
NMR (300 MHz, DMSO-d6) δ 7.61 (d, J = 9 Hz, 1H), δ 7.02 (t, J = 7.7 Hz, 1H), δ 6.99 – 6.85 (m, 
2H), δ 6.63 (ddd, J = 8.0, 2.6, 1.0 Hz, 1H), δ 5.15 (s, 2H), δ 3.81 – 3.65 (m, 1H), δ 1.90 (s, 3H), δ 




N-(1-(Adamantan-1-yl)ethyl)-4-aminobenzamide (3n): Yield: 0.22 g, 81%; Mp: 106-109°C. The 
product was obtained as a brown solid and was purified using hexane/acetone (5:1). 1H NMR (300 
MHz, DMSO-d6) δ 7.59 – 7.49 (m, 2H), δ 7.33 (d, J = 9.5 Hz, 1H), δ 6.54 – 6.45 (m, 2H), δ 5.50 
(s, 2H), δ 3.82 – 3.66 (m, 1H), δ 1.89 (s, 3H), δ 1.64 – 1.55 (m,  12H), δ 0.97 (d, J = 7.0 Hz, 3H). 
C29H26N2O . Purity:99% 
 
3-(((1-(Adamantan-1-yl)ethyl)amino)methyl)aniline (3o): Yield: 0.12 g, 48%; Mp: 165-168°C. 
The product was obtained as a dark brown solid and was purified using hexane/acetone (5:1).  1H 
NMR (300 MHz, DMSO-d6) δ 6.95 (t, J = 7.5 Hz, 1H), δ 6.58 – 6.32 (m, 4H), δ 5.01 (s, 2H), δ 3.66 
(d, J = 12.1 Hz, 2H), δ 2.11 (s, 1H), δ 1.91 (s, 3H), δ 1.58 (t, J = 10.2 Hz, 9H), δ 1.38 (d, J = 11.9 






6.3 Biological Assays 
6.3.1 Thioflavin-T (ThT) monitoring of Aβ40/42 aggregation kinetics.146,148 
 The ability of synthesized compounds to inhibit and/or modulate Aβ aggregation kinetics 
was determined using a ThT-based fluorescence assay. The assays were conducted using black, 
clear-bottom, Costar 384-well plates with 30 seconds of linear shaking at 730 cpm every 5 minutes 
at 37 °C for 24 h. The ThT excitation/emission was measured at 440 nm/490 nm and readings were 
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taken every 5 minutes using Biotek Synergy H1 microplate reader. Test compounds were prepared 
in DMSO and further diluted to 10 x in 215mM phosphate buffer at pH 7.4. The 
Aβ.Hexafluoroisopropanol (HFIP) samples (Aβ40 or Aβ42 obtained from rPeptide, USA) was 
dissolved in 1% ammonium hydroxide and sonicated for 5 minutes at room temperate and diluted 
to 50 μM in 215 mM phosphate buffer. ThT stock solution was prepared with 50 mM glycine and 
adjusted to pH 7.4 to give a 15 μM solution. Plating sequence was as follows:  
 ThT background: 44 μL ThT, 35 μL buffer, 1 μL DMSO 
 Aβ control: 44 μL ThT, 27 μL buffer, 1 μL DMSO 
 Compound screening: 44 μL ThT, 20 μL buffer 
Then 8 μL of 10x compound dilutions (concentrations tested: 1, 5 and 25 μM) were added and end 
point reading was measured to determine ThT-interference before finally adding 8 μL of  Aβ40 or 
Aβ42 stock solutions (5 μM final). Plates were sealed with a transparent plate film prior to initiating 
the assay. The relative fluorescence intensity units (RFU) were corrected for ThT-interference 
before processing the aggregation kinetic plots and inhibition percentages. Data presented was mean 
of triplicate reading of at least 2 independent experiments.   
 
 
6.3.2 Transmission Electron microscopy (TEM) 
80 μL of 215 mM phosphate buffer, 20 μL of 10 x test compound dilutions (250 μM – 
prepared in the same way as for the Aβ kinetic assay) and 100 μL of Aβ40 or Aβ42 stock solution (50 
μM) were added to a clear Costar, round-bottom 96-well plate. 2 μL of DMSO and 18 μL of 
phosphate buffer was added to the control wells. The final Aβ:test compound ratio was 1:1 at 25 
μM. Plate was incubated on a Fisher scientific plate incubator at 37 °C with constant shaking at 730 
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cpm for 24 h. TEM grids were prepared by adding 20 μL of incubated test compound and Aβ 
mixture to the 400 mesh, formvar-coated copper grids using eppendorf pipette. The grids were air-
dried in fume hood for a few hours before the buffer salts were washed by adding two drops of 
ultra-pure water (UPW) followed by quickly removing the water by small pieces of filter papers. 
The grids were air-dried and negatively stained by adding a drop of 2% phosphotungstic acid (PTA) 
and immediately dried using small pieces of filter paper. The grids were air-dried for at least 24 
hours prior to scanning. The images were produced using a Philips CM 10 transmission electron 




6.3.3  Computational Chemistry  
The molecular docking studies were conducted using the computational software Discovery 
Studio Client v17.1.0.16143 (Structure-Based-Design software), from BIOVIA Inc. San Diego, 
USA. The X-ray crystal structure of Aβ dimer and fibrils were obtained from RCSB Protein Data 
Bank (PDB id: 2LMN) and were prepared for docking study by adding hydrogens and by assigning 
CHARMm force field using the macromolecules module in the software. The ligand molecules 
were constructed using the Build Fragment tool and energy minimized using Steepest descent and 
Smart minimizer algorithms with 500 max steps. Ligand binding site was defined by selecting a 15 
Å sphere radius for both Aβ dimer and fibrils. Molecular docking experiments were carried out 
using the receptor-ligand interactions module of the software. The CDOCKER algorithm was 
chosen to produce the top ten binding modes of the compounds bound using CHARMm force field 
ranked based on the CDOCKER energies and CDOCKER interaction energies in kcal/mol. Then 
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Appendix 2: ChE IC50 values for a selected number of derivatives. 
 
Compound AChE(IC50 (μM)) BuChE(IC50 (μM)) 
2a >50 >50 
1f 17.9 >50 
2f 15.5 >50 
3f 14.5 >50 
2b 15.9 16.3 
3n 7.5 27.2 
2n 7.4 >50 
Donepezil  0.03 5.74 
 
The tested derivatives exhibited moderate inhibition for the AChE with IC50 values ranging from 
7.4 to >50 μM. Human ChE were used and the assay was conducted using Ellman’s method. Results 
are expressed as an average of triplicate mesuarments of three independent experiments (n = 3).   
